

TITLE: A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

PROTOCOL NUMBER: ML28801

VERSION NUMBER: 3

STUDIED DISEASE: Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer

STUDY INITIATOR: Roche Hellas S.A.

DATE FINAL: Version 1: 7-Jul-14

DATE(S) AMENDED: Version 2: 22-Dec-14
Version 3: 09-Feb-16

CONFIDENTIAL

The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered.

PROTOCOL AMENDMENT FINALIZATION SIGNATURE PAGE

TITLE: A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

PROTOCOL NUMBER: ML28801

VERSION NUMBER:

STUDIED DISEASE: Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer

STUDY INITIATOR: Roche Hellas S.A.

DATE AMENDED: 9-Feb-2016

This protocol amendment was finalized on the date shown above.

Scientific Responsible/NIS Data Science Responsible

Date

PROTOCOL AMENDMENT, VERSION 3: RATIONALE

Protocol ML28801 has been amended to meet the requirement of an update in standard operating procedures related to non-interventional studies.

The following changes were made:

- 1) Protocol transferred into a new internal template for non-investigational studies with studied medicines.
- 2) Clarified which non-serious adverse events should be collected and which should not.
- 3) Further clarified the definition of cardiac dysfunction in specific non-serious adverse event
- 4) Added the incidence of declines in left ventricular function below 50% as a safety variable
- 5) Modified section 10 to align with the requirement of a safety registry
- 6) Reorganized objectives in effectiveness measures
- 7) Corrected typographical errors and added clarifications where needed

Substantive new information appears in italics. This amendment represents cumulative changes to the original protocol.

PROTOCOL AMENDMENT, VERSION 3: SUMMARY OF CHANGES

SECTION 7.1: Study Design

300 patients are planned to be enrolled in approximately 10 sites in Greece. Enrollment will be opened for 3 years.

~~The frequency of subsequent visits will be determined by the treating physician, and routine clinical data will be collected approximately every 3 months from patient charts, clinical notes, and diagnostic and laboratory test results. Follow-up visits will be determined by the treating physician, but data will be collected approximately every 3 months, from patient charts, clinical notes, and diagnostic and laboratory test results.~~ All anti-cancer treatment changes, clinical outcomes (including disease progression), clinically relevant AEs and survival status will be collected.

Section 7.1.1: Overview of Study Design

~~This observational disease registry is a prospective, national, multicentre, non-interventional study designed to enrol patients who have an initial diagnosis of unresectable LA/mBC made up to 6 months prior to registry enrolment. These patients will be prospectively followed for at least 5 years after study enrolment to evaluate their anti-cancer treatments. Data on patients' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.~~

Because investigators will follow local, national or on-label guidelines, no specified assessments are to be captured, with the exception of specific adverse events that must be transmitted to the Sponsor. To guide investigators, a data collection overview of routine clinical assessments is provided in Appendix 1.

Section 7.2.1: Rationale for Patient Population

This is an observational study in which clinical decisions concerning the optimal management strategy for a particular patient are taken independent of and prior to any decision by the physician to invite a patient to participate in the study. *Written informed consent where local regulations allow or require it will be obtained prior to first data entry in the CRF.*

Due to the nature of this NIS, subgroup analyses will be defined once collected data are matured enough to define specific subgroups. Patients will be grouped according to treatment regimens received. Some analyses may exclude investigational regimens or regimens that do not include HER2-targeted treatment.

Section 7.3: Variables

- *Where available, the following safety parameters will be documented and examined per subgroups, if relevant: Comparative safety of various HER2-targeted treatment regimens and their combinations. This will be measured by summarizing and comparing SAEs*
- *Safety of Roche oncology products in a real-world setting.*
- *Summary statistics of AEs leading to discontinuation or dose modification of an anti-cancer therapy*
- *Estimation of the incidence and prevalence (during the observation period) of cardiac events related to left ventricular dysfunction, pregnancy and pregnancy outcomes*

For further descriptions about the AEs that will be collected, please refer to Section 7.4.2.4.

Section 7.5.1: Study Discontinuation

When a patient faces end of life and decides to enter the hospice for end of life cares, the patient shouldn't be considered as discontinued from the study, although the patient does not receive any anti-cancer treatment anymore. Instead data from patient's charts and note will continue to be transferred into the CRF until study discontinuation

Section 7.5.3: Discontinuation from Anti-Cancer Treatment

Discontinuation of anti-cancer treatment will not be considered to be a reason for study discontinuation and patients will continue to be followed through the different lines of anti-cancer treatment and until study discontinuation. The treating physician is encouraged to follow the patient for as long as possible, until patient death or through to study end

Section 7.7.3.3: Safety Analysis

- *Incidence of cardiac dysfunctions per line of treatment and type of anti-cancer therapy.*

SECTION 9: MANAGEMENT OF ADVERSE EVENTS

*Disease registries are recognized as a source of adverse event reporting, and while it is not a requirement to collect all AEs as part of a disease registry, any AEs which are collected in the course of the registry should be forwarded to the **Marketing Authorization Holder as solicited reports.***

In addition, the following should also be reported if occurring during exposure to a marketed medicinal product:

- pregnancy
- abnormal laboratory findings with or without associated AEs (see Section **Error! Reference source not found.**)
- overdose, abuse, misuse, medication error, occupational exposure with or without associated AEs
- reports of lack of efficacy
- drug interactions

Certain types of events require immediate reporting to the Sponsor, as outlined in Section 9.1.1

Section: 9.1.3.1: Immediate Reporting Requirements from Physician to Marketing Authorization Holder

Certain events require immediate reporting to allow the Marketing Authorization Holder and the regulatory authorities to take appropriate measures to address potential new risks associated with the use of the medicine. The physician must report such events to the marketing authorization holder immediately; under no circumstances should reporting take place more than 24 hours after the physician learns of the event. The following is a list of events that the physician must report to the marketing authorization holder within 24 hours after learning of the event, regardless of relationship to study medicine:

- SAEs
- Pregnancies

Section: 9.1.3.4: Reporting Requirements for Pregnancies

Female patients of childbearing potential will be instructed to immediately inform the physician if they become pregnant during the observation period. A Pregnancy Report should be completed by the physician immediately (i.e., no more than 24 hours after learning of the pregnancy and sent to Roche Drug Safety). Pregnancy should not be recorded on the AE CRF. Monitoring of the patient should continue until conclusion of the pregnancy. Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the AE section of the CRF.

Suspected adverse reactions that occur in infants following exposure to a medicinal product from breast milk should also be reported to Roche Drug Safety.

TABLE OF CONTENTS

PROTOCOL AMENDMENT FINALIZATION SIGNATURE PAGE	2
Section 7.7.3.3: Safety Analysis	5
<i>SECTION 9: MANAGEMENT OF ADVERSE EVENTS</i>	5
Section: 9.1.3.1: Immediate Reporting Requirements from Physician.....	6
to Marketing Authorization Holder	6
Section: 9.1.3.4: Reporting Requirements for Pregnancies	6
PROTOCOL AMENDMENT ACCEPTANCE FORM	11
1. LIST OF ABBREVIATIONS.....	12
2. RESPONSIBLE PARTIES	14
3. SYNOPSIS.....	15
4. PROTOCOL AMENDMENTS AND UPDATES	22
5. RATIONALE AND BACKGROUND.....	22
5.1 Background on HER2-POSITIVE METASTATIC BREAST CANCER	22
5.2 Background on TREATMENT OPTIONS FOR HER2-POSITIVE METASTATIC BREAST CANCER	23
5.3 Study Rationale AND BENEFIT-RISK ASSESSMENT	23
6. RESEARCH QUESTION AND OBJECTIVES.....	24
6.1 Research Question	24
6.2 Objectives	24
7. RESEARCH METHODS	25
7.1 Study Design	25
7.1.1 Overview of Study Design	26
7.1.2 Rationale for Disease Registry Design	26
7.1.3 Number of Patients Observed in the Disease Registry	27
7.1.4 Centers	27

7.2	Population.....	27
7.2.1	Rationale for Patient Population	28
7.3	Variables.....	28
7.3.1	Primary Effectiveness Variable.....	28
7.3.1.1	Anti-Cancer Treatment Pattern Measures.....	28
7.3.2	Secondary Effectiveness Variables	29
7.3.3	Safety Variables	29
7.3.4	Other Variables of Interest.....	30
7.3.4.1	Quality of Life Measures.....	30
7.3.4.2	Health Economic Outcome Measures	32
7.4	DATA COLLECTION.....	33
7.4.1	Data sources	33
7.4.2	Data Collected During the Observation Period	33
7.4.2.1	Patient Medical History.....	34
7.4.2.2	Demographics	35
7.4.2.3	Anti-Cancer and Concomitant Medications	35
7.4.2.4	Collection of Safety Information	36
7.4.2.5	Pregnancy Status and Pregnancy Outcomes.....	37
7.4.2.6	Performance Status.....	37
7.4.2.7	Quality of Life and Patient-Reported Outcomes	37
7.4.2.8	Health Economic Outcome Measurements	37
7.4.3	Data Collected at Study Completion.....	39
7.5	Patient, Study, and Site Discontinuation.....	39
7.5.1	Study Discontinuation	39
7.5.2	Study and Site Discontinuation.....	39
7.5.3	Discontinuation from Anti-Cancer Treatment.....	39
7.6	Data Management	40
7.6.1	Data Quality Assurance	40
7.6.2	Electronic Case Report Forms.....	41
7.6.3	Patient-Reported Outcome Data	41
7.6.4	Source Data Documentation.....	41
7.6.5	Use of Computerized Systems	42
7.6.6	Retention of Records.....	42

7.7	Statistical Considerations	43
7.7.1	General Considerations	43
7.7.2	Analysis Populations	43
7.7.3	Analysis Methods	43
7.7.3.1	Primary Effectiveness Analysis	44
7.7.3.2	Secondary Effectiveness Analysis.....	44
7.7.3.3	Safety Analysis.....	44
7.7.3.4	Other Analyses.....	45
7.7.4	Interim Analyses	48
7.7.5	Determination of Sample Size	48
7.8	Study Documentation and Monitoring.....	51
7.8.1	Study Documentation	51
7.8.2	Site Audits and Inspections	52
7.8.3	Administrative Structure.....	52
7.9	Limitations of the Research Method	52
7.10	Other Aspects.....	52
8.	PROTECTION OF HUMAN SUBJECTS.....	52
8.1	Compliance with Laws and Regulations	52
8.2	Informed Consent	53
8.3	Institutional Review Board or Ethics Committee	54
8.4	Confidentiality	54
9.	MANAGEMENT OF ADVERSE EVENTS	55
9.1	Adverse Events	55
9.1.1	Assessment of Serious Adverse Events (Immediately Reportable to the Marketing Authorization Holder) and Other Non-Serious Adverse Events	55
9.1.2	Methods and Timing for Capturing and Assessing Safety Parameters	56
9.1.2.1	Adverse Event Reporting Period	56
9.1.2.2	Procedures for Recording Adverse Events	57
9.1.3	Reporting Requirements from Physician to Marketing Authorisation Holder.....	58
9.1.3.1	Immediate Reporting Requirements from Physician to Marketing Authorization Holder	58

9.1.3.2	Reporting Requirements for Non-Serious Adverse Events	58
9.1.3.3	If EDC System is Temporarily Unavailable or not Used	59
9.1.3.4	Reporting Requirements for Pregnancies	59
9.1.4	Follow-Up of Patients after Adverse Events	59
9.1.4.1	Physician Follow-Up.....	59
9.1.4.2	Marketing Authorization Holder Follow-Up	59
9.2	Safety REPORTING Requirements for non-Studied Medicinal products.....	60
10.	PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS	60
11.	SAFETY RESULTS WILL BE BE PUBLISHED OR PRESENTED AT SCIENTIFIC MEETINGS. EFFECTIVENESS RESULTS MAY BE PUBLISHED PROVIDED THAT THE NUMBER OF PATIENTS ENROLLED IS SUFFICIENT. REFERENCES	62

LIST OF TABLES

Table 1.	Estimated 95% CIs for a Median Progression-free Survival of 10 Months	40
Table 2.	Estimated 95% Confidence Intervals for a Median Overall Survival of 24 Months	41
Table 3.	Estimated 95% Confidence Intervals for Different Event Rates.....	42
Table 4.	Probability of Detecting Occurrences for Different Event Rates	42

LIST OF APPENDICES

Appendix 1	Data Collection Overview.....	57
Appendix 2	Data Collected During the Observational Study.....	58
Appendix 3	ENCePP Checklist for Study Protocols (Revision 2).....	60
Appendix 4	Adverse Events.....	66

PROTOCOL AMENDMENT ACCEPTANCE FORM

TITLE: A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

PROTOCOL NUMBER: ML28801

VERSION NUMBER: 3

STUDIED DIASEASE: Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer

STUDY INITIATOR: Roche Hellas S.A.

I agree to conduct the study in accordance with the current protocol.

Treating Physician's Name (print)

Treating Physician's Signature

Date

Please retain the signed original of this form for your study files. Please return a copy to your local study monitor.

1. **LIST OF ABBREVIATIONS**

Abbreviation	Definition
AE	adverse event
ALT	alanine aminotransferase
APA	Alopecia Patient Assessment
AST	aspartate aminotransferase
CI	confidence interval
CR	complete response
CRO	contract research organization
CTCAE	common terminology criteria for adverse events
DoR	Duration of response
EC	Ethics Committee
eCRF	electronic Case Report Form
EDC	electronic data capture
ENCePP	European Network of Centres for Pharmacoeconomics and Pharmacovigilance
EORTC	European Organisation for Research and Treatment of Cancer
EORTC QLQ-BR23	EORTC Breast Cancer-specific Quality of Life Questionnaire core 23
EORTC QLQ-C30	EORTC Quality of Life Questionnaire core 30
ePRO	electronic patient-reported outcome
EQ-5D	EuroQol 5-Dimensions questionnaire
FACT-B	Functional Assessment of Cancer Therapy – Breast
GCP	Good Clinical Practice
GPP	Good Pharmacoeconomics Practices
GVP	Good Pharmacovigilance Practices
HER2	human epidermal growth factor receptor 2
HRQoL	Overall Health Related Quality of Life Questionnaire
ICF	Informed consent form
ICH	International Conference on Harmonization
IRB	Institutional Review Board
LA	locally advanced
LVEF	left ventricular ejection fraction
mBC	metastatic breast cancer
NCI	National Cancer Institute
ORR	objective response rate
OS	overall survival

Abbreviation	Definition
PASS	post-authorization safety study
PFS	progression-free survival
PNQ	Patient Neurotoxicity Questionnaire
PR	partial response
PRO	patient-reported outcome
QoL	quality of life
SAE	serious adverse event
SOC	system organ class
T-DM1	trastuzumab emtansine
WPAI	Work Productivity and Activity Impairment Questionnaire
ULN	upper limit of normal

2. RESPONSIBLE PARTIES

Main Author

[REDACTED]

Lead Scientific Responsible

[REDACTED]

3. SYNOPSIS

TITLE: A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

PROTOCOL NUMBER: ML28801

VERSION NUMBER: 3

DATE OF PROTOCOL: 9-Feb-2016

DISEASE REGISTRY: UMBTDM1: FollowHER

PHASE: IV, non-interventional study

INDICATION: HER2-positive unresectable locally advanced or metastatic breast cancer

STUDY INITIATOR:

[REDACTED]

MAIN AUTHOR:

[REDACTED]

Rationale and Background

Breast cancer is the most common cancer in women globally, in both the developed and the developing world, with approximately 1.38 million new cases diagnosed in 2008 (World Health Organization 2011). It is also the leading cause of cancer death in women, accounting for 458,400 deaths (14% of all cancer deaths) in 2008 (Jemal et al. 2011). Metastatic breast cancer (mBC) is incurable, with the primary goal of treatment being to extend life and palliate symptoms while preserving quality of life (QoL). Annually, almost 100,000 breast cancer-related deaths occur in patients whose tumors overexpress the human epidermal growth factor receptor 2 (HER2).

The number of anti-cancer treatment options available to patients with HER2-positive breast cancer is broad and may vary between countries, in terms of both the drugs used and the sequence in which they are used. Unpublished market research results revealed that the anti-HER2 targeted treatment most frequently used is trastuzumab, either alone or in combination. In first-line treatment, taxanes (paclitaxel or docetaxel) are frequently combined with trastuzumab, whereas in second- and third-line treatments, even though combinations are more diversified, vinorelbine and capecitabine are the leading agents to be combined with trastuzumab.

Other treatment options for patients with HER2-positive mBC include trastuzumab-emtansine (T-DM1), lapatinib, and pertuzumab, the latter being given in combination with trastuzumab. The treatment of HER2-positive mBC will continue to evolve as new agents become available.

There are limited published data concerning treatment patterns for patients with HER2-positive unresectable locally advanced (LA)/mBC. However, clinicians and reimbursement agencies may require such information to inform decision-making regarding the best treatment strategies for patients throughout the course of their disease.

This study will allow descriptive analyses to identify associations between patient risk factors, treatments and outcomes. Additionally, as new information becomes available on potential risk

factors and as new treatments become available, the study will provide an opportunity to gain an insight into the evolving treatment landscape.

Research Question and Objectives

Effectiveness Objectives

The primary effectiveness objective for this study is as follows:

- In patients with unresectable locally advanced (LA) or metastatic HER2 positive breast cancer (mBC),
 1. To estimate and describe progression-free survival (PFS)
 2. To describe treatment regimens and their sequencing

The secondary effectiveness objectives for this study are as follows:

- To observe and describe overall survival (OS)
- To observe duration of response (DoR) per anti-cancer treatment regimen
- To observe and describe objective response rate (ORR) per anti-cancer treatment regimen

Safety Objectives

The safety objectives for this study are as follows:

- To observe and describe the safety of different anti-cancer treatment regimens through the reporting of serious adverse events (SAEs) and AEs leading to discontinuation or dose modification of an anti-cancer therapy
- To observe and describe the incidence of and reasons for anti-cancer treatment modifications
- To document and describe the treatment of population of special interest by estimating the incidence and prevalence (during the observation period) of cardiac events related to left ventricular dysfunction, pregnancy and pregnancy outcomes
- To document the incidence (during the observation period) of AEs of interest related to the use of Roche products and their combination partners.

Other Objectives

- To observe the HER2 testing results and degree of overexpression
- To observe and describe country/regional differences in anti-cancer treatment regimens
- To observe and describe patients' demographics and breast cancer histories for each anti-cancer treatment regimen
- To measure the multidimensional health-related QoL using both a generic and a disease-specific patient reported outcome (PRO) instrument per anti-cancer treatment regimen
- To assess the patient-reported work productivity loss and daily activity impairment attributable to general health among the different anti-cancer treatment regimen cohorts.
- To estimate the HER2 retesting rate prior to study enrolment or during the study among the overall study population

Health Economic Assessment Objectives

- To examine the healthcare resource utilisation, in the inpatient and outpatient settings, associated with various anti-cancer treatment regimens including the consumption of resources for the management of associated AEs, as of the time of unresectable LA/mBC diagnosis
- To depict the overall disease burden in terms of the all-cause healthcare resource utilisation among the different anti-cancer treatment regimen cohorts, from the time of unresectable LA/mBC diagnosis until the completion of the study observation period.

Study Design

Description of Study

This disease registry is a prospective, multicentre non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrolment. Enrolled patients will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Once a patient is enrolled in the study, she/he will be followed until death, withdrawal of consent or study termination, whichever occurs first.

No treatment regimen is mandated by this protocol.

This is a disease registry in which clinical decisions concerning the optimum management strategy for a particular patient are to be taken independent of and/or prior to any decision by the physician to invite a patient to participate in the study. The treating physician will make all treatment decisions according to his/her regular practice independent of this study.

Start Date of Study:

The study start date will be the date of the first data collection: the date from which information on the first study subject is recorded in the study database or, in the case of secondary use of data, the date from which data extraction starts.

End of Study

The end of the study will be the date from which the last information of the last subject is recorded in the study database.

Length of Study:

This study will last approximately 8 years.

Target Population

The target population for inclusion in this study is patients with HER2-positive unresectable LA/mBC, where the initial diagnosis of LA/mBC has been made no more than 6 months prior to enrolment.

Patients must meet the following criteria for study entry:

- Male or females
- Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrolment, although they can have received anti-cancer treatment during that time
- Age \geq 18 years

Able and willing to provide written informed consent and to comply with the study protocol.

There are no exclusion criteria for entry into this study.

Variables

Only variables, obtained according to routine clinical practice can and should be documented in this study.

Primary Effectiveness Variables

The effectiveness variables for this study are as follows:

- Progression free survival
- Unique treatment regimen frequency, distribution, and sequencing in patients with HER2-positive unresectable LA/mBC

Secondary Effectiveness Variables

The secondary effectiveness variables for this study are as follows and documented when available:

- Overall survival
- Duration of response

FollowHER—F. Hoffmann-La Roche Ltd

Protocol ML28801, Version 3

- Objective response rate
- The number of treatment regimens received by patients

Safety Variables

Where available, the following safety parameters will be documented:

- Comparative safety of various HER2-targeted treatment regimens and their combinations. This will be measured by summarizing and comparing SAEs
- Safety of Roche oncology products in a real-world setting.
- Summary of AEs leading to discontinuation or dose modification of an anti-cancer therapy
- Estimation of the incidence and prevalence (during the observation period) of cardiac events related to left ventricular dysfunction, pregnancy and pregnancy outcomes

In addition, the treatment regimens and sequencing patterns will be reflected through the following measures:

- Proportion of patients receiving each treatment regimen overall and per line of therapy (i.e., first-line versus subsequent-line therapy) as of the diagnosis with unresectable LA/mBC
- Proportion of patients receiving each unique treatment regimen sequence (applicable for patients who receive more than one treatment regimen following unresectable LA/mBC diagnosis)
- Regional differences in the distribution of patients receiving unique treatment regimens or sequences of treatment regimen by urban, semi-urban and rural settings.

Other Variables of Interest

Where available, the following parameters will be documented:

- Measure of association between patient characteristics and prescription of particular anti-cancer treatment regimens
- Measure of association between patient characteristics and particular anti-cancer treatment regimens effectiveness
- Patient reported outcomes where it is routine clinical practice
- Resource utilization including associated procedures, hospitalizations, emergency room attendances and outpatient visits
- Healthcare resource utilisation (e.g. hospitalisations, emergency room attendances and outpatient visits) associated with various anti-cancer treatment regimens including the management of associated AEs.
- Healthcare resource utilisation due to any reason, among the different anti-cancer treatment regimen cohorts, from the time of unresectable LA/mBC diagnosis until the completion of the study observation period.
- Disease (unresectable LA/mBC)-related out-of-pocket healthcare expenditures.
- Other disease-related indirect costs
- Specifically the following will be recorded, as per local clinical practice:
 - Number (n) and length of hospitalisations, emergency room attendances or admissions to an outpatient facility and visits at office-based physicians as well as medical procedures/interventions/investigations/medications associated with the occurrence and management of the treatment-related adverse events throughout the study follow-up period.
 - Monthly out-of-pocket expenses for the disease including private expenditures for pharmaceuticals, primary care, secondary care, diagnostic/laboratory examinations, nursing home care and transportation to health care facilities.

- Number of working hours missed among informal caregivers due to disease-related caregiving responsibilities.
- Any monetary social benefits that the patient receives due to her condition.

Data Sources

Source data for patient data and healthcare resource utilization data will be taken from the patient's chart and other medical records and reported by means of a web based electronic data collection system.

PROs will be collected via a self-completed questionnaire during routine clinic visits.

Study Size

All eligible patients can be invited to participate in the study and should be enrolled sequentially. No other pre-selection criteria should be applied.

This study will recruit a minimum of 100 patients per year over approximately 3 years from the time this protocol is approved by the Hospital's Institutional Review Board/Ethics Committee.

Studied Medicinal Product All medicinal products used to treat metastatic breast cancer are considered studied in this local disease registry.

Statistical Considerations

The study will be analysed according to the separate Statistical Analysis Plan. Effectiveness, PRO and other measures will be analyzed using methods that will be dependent upon local endpoints and sampling design. These data will also be analyzed in subgroups according to study design, patient population and other relevant factors.

Analysis Methods

The full analysis set will comprise all enrolled patients; this will be the primary analysis population for safety and effectiveness parameters. Other analysis populations may be defined based on more restrictive criteria, such as patients receiving a particular anti-cancer treatment.

The analysis of the present study will be exploratory and primarily make use of descriptive statistical methods. In addition, exploratory statistical testing and modelling will be used to highlight interesting aspects of the data. Any test performed will be two-sided and carried out with a 5% α error rate without correction for multiplicity.

Primary and Secondary Effectiveness Analysis

The analysis of PFS and OS is based on the survivor function, which is the probability of remaining event free beyond a certain point in time. The survival function will be estimated using Kaplan–Meier methodology and summarized using the range, the 25th and 75th percentiles, the median overall survival and a 95% CI for the median. The plot of Kaplan–Meier estimates for each treatment regimen will be presented.

Effectiveness will be measured as follows:

- PFS for each anti-cancer treatment regimen: PFS will be calculated from the start date of a treatment regimen to the date of either disease progression or death.

A treatment regimen is defined as: any anti-cancer medication, used as a single agent or as part of a combination of medications, given from the date of initiation until the date of disease progression. If during the time elapsed between two disease-progression events a sequence of medications is used, this will count as one regimen. For example, a patient diagnosed with metastatic disease receives trastuzumab and docetaxel. After 3 cycles the docetaxel must be discontinued and the patient continues with trastuzumab and tamoxifen therapy. The use of trastuzumab, docetaxel and antihormonal therapy will be considered as one regimen.

- OS: defined as the date from initiation of treatment to the date of death from any cause.
- ORR for each anti-cancer treatment regimen: defined as the proportion of patients with either a complete response (CR) or partial response (PR), based on their overall response. Response will be evaluated by the Investigator according to site-/country-specific medical practice.

- DoR for each treatment regimen: defined as the time from date of first response (CR or PR) to the date of disease progression, as per Investigator assessment.

Safety Outcome Measures

A descriptive analysis of safety will be performed. The main safety parameter is the incidence of SAEs. The proportion of patients experiencing at least one event with each anti-cancer treatment regimen will be estimated with 95% Clopper–Pearson confidence intervals (CIs).

The following safety parameters will be evaluated:

- Comparative safety of various HER2-targeted treatment regimens and their combinations.
- Safety of Roche oncology products in a real-world setting.
- AEs leading to discontinuation or dose modification of an anti-cancer therapy
- Estimation of the incidence and prevalence (during the observation period) of cardiac events related to left ventricular dysfunction, pregnancy and pregnancy outcomes

Other Analyses

Quality of Life Measures

PRO measures that capture QoL data will be used in this study where it is routine clinical practice. PROs will be collected at study enrolment and periodically throughout study participation, including at the clinic visit at approximately at 3-month intervals throughout the study period and during clinic visits that are determined by the treating physician (no specific visits will be mandated for collecting these data).

The following PROs will be used in this study:

- EuroQol 5-Dimensions questionnaire (EQ-5D; Rabin and de Charro 2001)
- Functional Assessment of Cancer Therapy Breast (FACT-B), assessing overall health status (Brady 1997)
- Work Productivity and Activity Impairment (WPAI) questionnaire: for patients who are working (Reilly Associates 2002)

Health Economic Outcome Measures

- Healthcare costs and resource utilization (e.g. hospitalizations, emergency room attendances and outpatient visits) associated with various anti-cancer treatment regimens including the cost of treating associated AEs
- Healthcare resource utilisation due to any reason, among the different anti-cancer treatment regimen cohorts, from the time of unresectable LA/mBC diagnosis until the completion of the study observation period.
- Disease (unresectable LA/mBC)-related out-of-pocket healthcare expenditures.
- Other disease-related indirect costs
- Specifically the following will be recorded, as per local clinical practice:
 - Number (n) and length of hospitalisations, emergency room attendances or admissions to an outpatient facility and visits at office-based physicians as well as medical procedures/interventions/investigations/medications associated with the occurrence and management of the treatment-related adverse events throughout the study follow-up period.
 - Monthly out-of-pocket expenses for the disease including private expenditures for pharmaceuticals, primary care, secondary care, diagnostic/laboratory examinations, nursing home care and transportation to health care facilities.
 - Number of working hours missed among informal caregivers due to disease-related caregiving responsibilities.
 - Any monetary social benefits that the patient receives due to her condition

Interim Analyses

There will be annual interim analyses for safety reporting and presentation of safety results. These annual reporting events will start 1 year after the first patient visit and will continue annually until study end.

Sample Size Justification

This study has a planned sample size of approximately 300 patients. Patients will be enrolled in approximately 10 sites in Greece. Enrollment will be opened for 3 years. The primary effectiveness objective of the study is to observe treatment regimens and their sequencing and to describe treatment outcomes (PFS) in individual treatment groups. The planned sample size is intended to provide a sufficient number of patients to allow the assessment of overall trends by subgroups of common anti-cancer treatment regimens.

4. PROTOCOL AMENDMENTS AND UPDATES

Any protocol amendments will be prepared by the Sponsor or designee.

Protocol amendments will be submitted to the Institutional Review Board (IRB)/Ethics Committee (EC) and to regulatory authorities in accordance with local regulatory requirements.

Approval must be obtained from the IRB/EC and regulatory authorities (as locally required) before implementation of any changes, except for changes that involve logistical or administrative aspects only (e.g., change in Study Monitor or contact information).

Amendment 1

The protocol was modified to meet the requirement of an update in standard operating procedures related to non-interventional studies.

The following changes were made:

- 1) Protocol transferred into a new internal template for non-investigational studies with studied medicines.
- 2) Clarified which non-serious adverse events should be collected and which should not.
- 3) Further clarified the definition of cardiac dysfunction in specific non-serious adverse event
- 4) Added the incidence of declines in left ventricular function below 50% as a safety variable
- 5) Modified section 10 to align with the requirement of a safety registry
- 6) Reorganized objectives in effectiveness measures
- 7) Corrected typographical errors and added clarifications where needed

5. RATIONALE AND BACKGROUND

5.1 BACKGROUND ON HER2-POSITIVE METASTATIC BREAST CANCER

Breast cancer is the most common cancer in women globally, in both the developed and the developing world, with approximately 1.38 million new cases diagnosed in 2008 (World Health Organization 2011). It is also the leading cause of cancer death in women, accounting for 458,400 deaths (14% of all cancer deaths) in 2008 (Jemal et al. 2011). Metastatic breast cancer (mBC) is incurable, with the primary goal of treatment being to extend life and palliate symptoms while preserving quality of life (QoL). Annually, almost 100,000 breast cancer-related deaths occur in patients whose tumours overexpress the human epidermal growth factor receptor 2 (HER2).

The HER tyrosine kinase receptor family comprises four receptors: HER1, HER2, HER3 and HER4. These receptors are important mediators of cell growth, survival and differentiation (Sundaresan et al. 1999). Activation of HER receptors leads to receptor dimerization and cell signalling through the phosphatidylinositol 3-kinase/AKT pathway for promotion of tumour cell survival and through the mitogen-activated protein kinase pathway for cellular proliferation.

Overexpression of HER2 is observed in approximately 15–20% of human breast cancers (Owens et al. 2004). Several lines of scientific and clinical evidence support a direct role

for HER2 overexpression in the aggressive growth and poor clinical outcomes associated with these tumours (Slamon et al. 1987).

5.2 BACKGROUND ON TREATMENT OPTIONS FOR HER2-POSITIVE METASTATIC BREAST CANCER

The number of anti-cancer treatment options available to patients with HER2-positive breast cancer is broad and may vary between countries, in terms of both the drugs used and the sequence in which they are used. However, a recent market research study showed that during the course of HER2-positive breast cancer disease, the anti-HER2 targeted treatment most frequently used is trastuzumab, either alone or in combination (unpublished data held on file with Roche). In first-line treatment, taxanes (paclitaxel or docetaxel) are frequently combined with trastuzumab, whereas in second- and third-line treatments, even though combinations are more diversified, vinorelbine and capecitabine are the leading agents to be combined with trastuzumab.

Other newer treatment options for patients with HER2-positive mBC include trastuzumab-emtansine (T-DM1) and pertuzumab, the latter being given in combination with trastuzumab. The treatment of HER2-positive mBC will continue to evolve as new agents become available.

5.3 STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT

There are limited published data concerning treatment patterns for patients with HER2-positive unresectable locally advanced (LA)/mBC. However, clinicians and reimbursement agencies may require such information to inform decision-making regarding the best treatment strategies for patients throughout the course of their disease.

This study will allow descriptive analyses to identify associations between patient risk factors, treatments and outcomes. Additionally, as new information becomes available on potential risk factors and as new treatments become available, the study will provide an opportunity to gain an insight into the evolving treatment landscape.

As no therapeutic intervention is mandated by this protocol and no investigational product is used in the study, with only routine care being observed, there are no additional risks for participating patients. The study is non-interventional; initial treatment decisions will be made independent of a patient's participation in the study. Hence, no explicit additional potential benefits are expected from participation. The benefit is not for the individual patient but instead may be for the broader patient population as the disease and its treatment will be better understood. Other than possibly requiring additional patient time at routine clinic attendances, there are no anticipated costs associated with a patient's participation. Therefore, the benefit–risk balance for this study is considered to be neutral for an individual patient but overall it is considered favourable for the wider patient population with HER2-positive LA/mBC.

6. RESEARCH QUESTION AND OBJECTIVES

6.1 RESEARCH QUESTION

This observational disease registry is a prospective, multicentre non-interventional study designed to observe clinical outcomes, patient-reported outcomes (PROs), QoL and health economics across anti-cancer treatment regimens and sequences during the course of HER2-positive unresectable LA/mBC.

6.2 OBJECTIVES

Effectiveness Objectives

The primary effectiveness objective for this study is as follows:

- In patients with unresectable locally advanced (LA) or metastatic HER2 positive breast cancer (mBC),
 1. To estimate and describe progression-free survival (PFS)
 2. To describe treatment regimens and their sequencing

•

The secondary effectiveness objectives for this study are as follows:

- To observe and describe overall survival (OS)
- To observe duration of response (DoR) per anti-cancer treatment regimen
- To observe and describe objective response rate (ORR) per anti-cancer treatment regimen

Safety Objectives

The safety objectives for this study are as follows:

- To observe and describe the safety of different anti-cancer treatment regimens through the reporting of serious adverse events (SAEs) and AEs leading to discontinuation or dose modification of an anti-cancer therapy
- To observe and describe the incidence of and reasons for anti-cancer treatment modifications
- To document and describe the treatment of population of special interest by estimating the incidence and prevalence (during the observation period) of cardiac events related to left ventricular dysfunction, pregnancy and pregnancy outcomes
- To document the incidence (during the observation period) of specific AEs related to the use of Roche products and their combination partners.

Other Objectives

- To observe the HER2 testing results and degree of overexpression
- To observe and describe country/regional differences in anti-cancer treatment regimens

- To observe and describe patients' demographics and breast cancer histories for each anti-cancer treatment regimen
 - To measure the multidimensional health-related QoL using both a generic and a disease-specific patient reported outcome (PRO) instrument per anti-cancer treatment regimen
 - To assess the patient-reported work productivity loss and daily activity impairment attributable to general health among the different anti-cancer treatment regimen cohorts.
 - To estimate the HER2 retesting rate prior to study enrolment or during the study among the overall study population

Health Economic Assessment Objectives

- •To examine the healthcare resource utilisation, in the inpatient and outpatient settings, associated with various anti-cancer treatment regimens including the consumption of resources for the management of associated AEs, as of the time of unresectable LA/mBC diagnosis
- •To depict the overall disease burden in terms of the all-cause healthcare resource utilisation among the different anti-cancer treatment regimen cohorts, from the time of unresectable LA/mBC diagnosis until the completion of the study observation period.

7. RESEARCH METHODS

7.1 STUDY DESIGN

This disease registry is a prospective, multicentre non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrolment. Approximately 300 patients are planned to be enrolled in approximately 10 sites in Greece. Enrollment will be opened for 3 years. Enrolled patients will be prospectively followed for at least 5 years after study enrolment to evaluate their anti-cancer treatments. Enrolled patients will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.

Data regarding patient characteristics, breast cancer history and prior anti-cancer treatments for their breast cancer (including neoadjuvant, adjuvant and advanced settings) will be collected at enrolment.

Patients may also be concurrently enrolled in an interventional clinical trial in which case their study treatment(s) will be recorded, if open label and known, otherwise they will be recorded as "investigational treatment".

The frequency of subsequent visits will be determined by the treating physician, and routine clinical data will be collected approximately every 3 months from patient charts, clinical notes, and diagnostic and laboratory test results. All anti-cancer treatment

changes, clinical outcomes (including disease progression), clinically relevant AEs and survival status will be collected. Patient source data and healthcare resource utilization data will be taken from the patient's medical records and reported by means of a web-based electronic data collection (EDC) system. PROs will be collected via self-administered paper questionnaires completed by the patient themselves or via interviews (where applicable) during routine clinical visits at approximately 3-month intervals throughout study participation. Patients will be considered "on study" until death, withdrawal of consent, loss to follow-up, or end of study whichever comes first. This study will be analysed according to the separate study Statistical Analysis Plan.

The study is designed with only one "on study" observational period and no follow-up period or visit frequency is imposed. Patients will be considered "on study" until death, withdrawal of consent, loss to follow-up, or end of study, whichever comes first.

This study will be analysed according to a separate study Statistical Analysis Plan.

The Investigator should maintain a log of patient information (hospital/clinic identification numbers, names, addresses, telephone numbers, and hospital numbers, if applicable) for both patients who choose to participate and those who choose not to participate in the study. The log document should be maintained in strict confidence by the Investigator and will not be submitted to the Sponsor.

7.1.1 Overview of Study Design

Because investigators will follow local, national or on-label guidelines, no specified assessments are to be captured, with the exception of specific adverse events that must be transmitted to the Sponsor.

To guide investigators, a data collection overview of routine clinical assessments is provided in Appendix 1.

7.1.2 Rationale for Disease Registry Design

As the objective of this observational disease registry is to observe patterns of treatment for patients with unresectable LA/mBC, the study does not stipulate any specific treatments or dosing regimens. The specific treatment, dose and treatment duration will be decided by the Investigator independent of a patient's participation in the study and according to the approved product information, local treatment guidelines and/or routine clinical practice.

This observational disease registry will capture important data on the clinical characteristics of patients and their breast cancer at study enrolment. Patients will then be followed throughout the course of their disease to capture both the sequence of anti-cancer treatments and their corresponding treatment-specific, as well as overall, outcomes.

The data captured will allow both descriptive and inferential comparative analyses to be made to evaluate associations between patient risk factors, treatments and outcomes. Safety and effectiveness data will be collected in local (Daughter) studies and transferred to a global database for a pooled analysis.

This registry will provide an opportunity to gain a better understanding of decision-making regarding treatments across various stages of LA/mBC and how these might be influenced by patient factors (e.g. presence or absence of central nervous system metastases). It will also allow insight into the treatment landscape as it evolves.

7.1.3 Number of Patients Observed in the Disease Registry

All eligible patients can be invited to participate in the study and should be enrolled sequentially. No other pre-selection criteria should be applied.

This disease registry will enroll approximately 300 patients over 3 years from the time this protocol is approved by the country Institutional Review Board (IRB)/Ethics Committee (EC).

7.1.4 Centers

The study will be performed at approximately 10 centers in Greece. An appropriate number of sites will be opened to ensure that the recruitment target is reached within 3 years.

Additional countries and centers may be added or substituted if underperforming.

For this study, the type of healthcare site (e.g. specialty care, private practice, teaching institution, etc.) will be collected and documented only once in the electronic Case Report Form (eCRF) for each participating site.

7.2 POPULATION

Inclusion Criteria

Patients must meet the following criteria for study entry:

- Males or females
- Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrolment, although they can have received anti-cancer treatment during that time
- Age \geq 18 years
- Able and willing to provide written informed consent and to comply with the study protocol.

Exclusion Criteria

There are no exclusion criteria for entry into this study.

7.2.1 Rationale for Patient Population

The target population for inclusion in this study is patients with HER2-positive unresectable LA/mBC, where the initial diagnosis of LA/mBC has been made no more than 6 months prior to enrolment.

To minimize patient selection bias, the Investigator (or sub-Investigator) should invite all eligible consecutive patients. The sites are asked to maintain a screening log which will not have to be submitted to the Sponsor.

This is an observational study in which clinical decisions concerning the optimal management strategy for a particular patient are taken independent of and prior to any decision by the physician to invite a patient to participate in the study. Written informed consent where local regulations allow or require it will be obtained prior to first data entry in the CRF.

Due to the nature of this NIS, subgroup analyses will be defined once collected data are matured enough to define specific subgroups. Patients will be grouped according to treatment regimens received. Some analyses may exclude investigational regimens or regimens that do not include HER2-targeted treatment.

7.3 VARIABLES

7.3.1 Primary Effectiveness Variable

The effectiveness variables for this study are as follows:

- PFS for each treatment regimen: PFS will be calculated from the start date of an anti-cancer treatment regimen to the date of either disease progression or death.
- Number and proportion of patients receiving each unique treatment, where treatment can be a combination of anti-cancer therapies.
- Treatment sequences
- First-line anti-cancer treatment versus subsequent-line therapy, where first-line is defined therapies received after initial diagnosis of HER2 positive unresectable LA/mBC and before a patient experiences their first disease progression event

7.3.1.1 Anti-Cancer Treatment Pattern Measures

At study entry, all prior anti-cancer treatments for HER2-positive breast cancer (including in the neoadjuvant, adjuvant and advanced settings) will be captured retrospectively. All following anti-cancer therapies will then be captured prospectively during the observation period. Anti-Cancer treatments (and the associated data collected) include:

- Radiation treatment (including date, body site, dose and type of radiation)
- Chemotherapy (including names, dates, doses, number of cycles per regimen and reasons [if any] for discontinuation)

- Hormonal treatment (including agent name, administration route, date, dose and reasons [if any] for discontinuation)
- Immunotherapy (including agent name, administration route, date, dose, number of cycles per regimen and reasons [if any] for discontinuation)
- Other anti-cancer treatments including targeted therapy (including agent name, administration route, date, dose, number of cycles per regimen and reasons [if any] for discontinuation)
- Surgery (including date, body site and type of procedure)

A treatment regimen is defined as: any anti-cancer medication, used as a single agent or as part of a combination of medications given from the date of initiation until the date of disease progression. If during the time elapsed between two disease-progression events a sequence of medications is used, this will count as one regimen. For example, a patient diagnosed with metastatic disease receives trastuzumab and docetaxel. After 3 cycles the docetaxel must be discontinued and the patient continues with trastuzumab and tamoxifen therapy. The use of trastuzumab, docetaxel and anti-hormonal therapy will be considered as one regimen.

7.3.2 Secondary Effectiveness Variables

- OS: defined as the date from initiation of treatment to the date of death from any cause.
- DoR for each anti-cancer treatment regimen: defined as the time from date of first response (CR or PR) to the date of disease progression, as per Investigator assessment.
- ORR for each treatment regimen: defined as the proportion of patients with either complete response (CR) or partial response (PR), based on their overall response. Response will be evaluated by the Investigator according to site-/country-specific medical practice.
- Patient characteristics associated with receipt of particular anti-cancer treatment regimens
- The number of treatment regimens received by patients

7.3.3 Safety Variables

- Where available, the following safety parameters will be documented and examined per subgroups, if relevant: Comparative safety of various HER2-targeted treatment regimens and their combinations. This will be measured by summarizing and comparing SAEs
- Safety of Roche oncology products in a real-world setting.
- Summary statistics of AEs leading to discontinuation or dose modification of an anti-cancer therapy

- Estimation of the incidence and prevalence (during the observation period) of cardiac events related to left ventricular dysfunction, pregnancy and pregnancy outcomes

For further descriptions about the AEs that will be collected, please refer to Section 7.4.2.4.

7.3.4 Other Variables of Interest

Where available, the following parameters will be documented:

- Measure of association between patient characteristics and prescription of particular anti-cancer treatment regimens
- Measure of association between patient characteristics and particular anti-cancer treatment regimens effectiveness

7.3.4.1 Quality of Life Measures

PRO measures that capture quality of life (QoL) data will be used in this study where it is routine clinical practice. PROs will be collected at study enrolment and periodically throughout study participation, including at the clinic visit at approximately 3-month intervals throughout the study period and during clinic visits that are determined by the treating physician (no specific visits will be mandated for collecting these data).

The following PROs will be used in this study:

- **EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L); a generic HRQoL questionnaire (Herdman et al. 2011; EQ-5D-5L user guide 2013).**

The EQ-5D was developed by the EuroQol Group as a simple, generic measure of health-related QoL (HRQoL) for clinical and economic appraisal (Yfantopoulos et al. 2001; EuroQol 1990) and has been widely used in both general and specific disease populations. EQ-5D is designed for self-completion by respondents and is ideally suited for use in clinics, and in face-to-face interviews. It is cognitively not demanding, taking only a few minutes to complete.

The EQ-5D-3 Level version (EQ-5D-3L) was introduced in 1990 and it essentially consists of the EQ-5D descriptive system -comprising five dimensions, each with 3 levels of severity (no problems, some problems, extreme problems)- and the EQ-VAS (Rabin and de Charro 2001). A new five-level version of the EQ-5D (EQ-5D-5L) has been recently developed by the EuroQol Group (Herdman et al. 2011). The EQ-5D-5L has been demonstrated to be a valid extension of the three-level system, while improving the measurement properties of the EQ-5D-3L by reducing the ceiling and improving discriminatory power, and establishing convergent and known-groups validity (Janssen et al. 2013).

The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels of severity (no problems, slight problems, moderate problems, severe problems, and extreme problems). The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. The EQ-VAS records the respondent's self-rated health on a vertical, visual analogue graduated (0–100) scale where the endpoints are labelled 'Worst imaginable health state' and 'Best imaginable health state' and with higher scores indicating higher HRQoL. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.

The Greek version of EuroQol EQ-5D-5L will be used in order to measure patient's HRQoL at enrolment and at approximately 3-month intervals.

- **Functional Assessment of Cancer Therapy Breast (FACT-B); a disease-specific questionnaire assessing overall health status (Brady et al. 1997)**

The FACT-B (version 4) is a 37-item questionnaire designed to assess the multidimensional QoL of patients with breast cancer (Brady et al. 1997). The FACT-B consists of the Functional Assessment of Cancer Therapy-General (FACT-G) 27-item questionnaire and the 10-item breast cancer-specific subscale (BCS). A total of 5 dimensions are included in the FACT-B: the physical well-being (PWB, 7 items); the social/family well-being (SWB, 7 items); the emotional well-being (EWB, 6 items); the functional well-being (FWB, 7 items) and the BCS (10 items). Responses capture the state of well-being over the past seven days. All answers are rated on a 0-4 scale. Higher overall scores represent a better QoL. A total FACT-B score can be generated which takes into account all 37 items of the questionnaire (score range 0-148). However, the BCS score can also be calculated separately (score range: 0-40) as can the Treatment Outcome Index (TOI-PFB) comprised of the sum of scores in the subscales of PWB, FWB and BCS (score range: 0-96).

The FACT-B has been demonstrated to have high internal consistency, reliability and sensitivity to change and has been well-validated (Brady et al. 1997; Cella et al. 1993).

The FACT-B scale is designed for patient self-administration, but can also be administered by interview format. Interview administration is considered appropriate after adequate training of interviewers so as to elicit non-biased patient response. In the present study the Greek version of the questionnaire will be used.

- **Work Productivity and Activity Impairment-General Health (WPAI-GH) questionnaire (Reilly Associates 2002)**

Work productivity and activity impairment will be evaluated using the Greek version of the WPAI:GH v1.0 questionnaire which is either self- or interviewer- administered (Reilly

Associates 2002). The questionnaire will be completed by all patients at approximately 3-month intervals throughout the study regardless of their employment status.

The WPAI:GH is a 6-item, quantitative, self-reported evaluation of the level of absenteeism, presenteeism, and daily activity impairment attributable to general health during the prior 7 days (Reilly et al. 1993).

It comprises six questions that capture the following information:

1. employment status;
2. hours of work missed due to health problems;
3. hours missed because of other reasons;
4. hours actually worked;
5. the degree to which health has affected productivity while working from 0 (no effect) to 10 (maximum impairment); and
6. the degree to which health affected other (non-work) regular activities (0–10).

The recall period for the questions 2 to 6 is seven days. Four main outcomes will be generated from the WPAI-GH and expressed in percentages by multiplying the following scores by 100:

- 1) Absenteeism: percent work time missed due to health = $Q2/(Q2 + Q4)$ for those who were currently employed;
- 2) Presenteeism: percent impairment while working due to health = $Q5/10$ for those who were currently employed and actually worked in the past seven days;
- 3) Absenteeism plus presenteeism: percent overall work impairment due to health $Q2/(Q2 + Q4) + ((1 - Q2/(Q2 + Q4)) \times (Q5/10))$ for those who were currently employed;
- 4) Activity impairment: percent activity impairment due to health $Q6/10$ for all respondents. For those who missed work and did not actually work in the past seven days, the percent overall work impairment due to health will be equal to the percent work time missed due to health.

7.3.4.2 Health Economic Outcome Measures

- Healthcare costs and resource utilization (e.g. hospitalizations, emergency room attendances and outpatient visits) associated with various anti-cancer treatment regimens including the cost of treating associated AEsHealthcare resource utilisation due to any reason, among the different anti-cancer treatment regimen cohorts, from the time of unresectable LA/mBC diagnosis until the completion of the study observation period.
- Disease (unresectable LA/mBC)-related out-of-pocket healthcare expenditures.
- Other disease-related indirect costs.
- Specifically the following will be recorded:
 - Number (n) and length of hospitalisations, emergency room attendances or admissions to an outpatient facility and visits at office-based physicians as well as medical procedures/interventions/investigations/medications due to any cause including those associated with the occurrence and management of the treatment-related adverse events throughout the study observation period.
 - Monthly out-of-pocket expenses for the disease including private expenditures for pharmaceuticals, primary care, secondary care, examinations, nursing home care and transportation to health care facilities.
 - Number of working hours missed among informal caregivers due to disease-related caregiving responsibilities.
 - Any monetary social benefits that the patient receives due to her condition.

7.4 DATA COLLECTION

7.4.1 Data sources

Patients' charts and other medical records will be the source of routine clinical data that will be recorded in the CRFs. Therefore, only data available and already existing in patient's files will be recorded in CRFs.

PROs will be collected via a self-completed questionnaire during routine clinic visits..

The degree of detail and completeness of data collected is dependent on what is recorded in the patient charts. For clinical monitoring reasons, physicians are encouraged to provide sufficient details in the patient's record to allow proper CRF data entry (see Section 7.8). Data will be collected approximately every 3 months from patient charts, clinic notes, and diagnostic tests and labs.

7.4.2 Data Collected During the Observation Period

During the observational period, patients will receive anti-cancer therapy and routine laboratory tests will be performed. Available results from the range of assessments described below will be documented on the CRF (non-exhaustive list). Most data will be documented around the time when the treating physician meets the patient.

In the routine care setting, patients are seen regularly by their treating physicians either for treatment or for regular assessment after treatment, such as monitoring the left

ventricular ejection fraction. Thus, no study-specific visits or evaluations are required by this protocol. It is up to the treating physician to perform and document the assessments as performed in the real clinical setting.

Please see Appendix 2 for the data collection overview.

It is recommended that the following data are collected approximately every 3 months at routine clinic visits.

- Medical history (Section 7.4.2.1)
- Breast cancer history (e.g. surgical procedures, sites of metastases, disease status; Section 7.4.2.1)
- Anti-cancer treatments (Section 7.3.1.1, Section 7.4.2.3 and Section 7.5.3), including any changes and reasons for them
- Concomitant medications (Section 7.4.2.3 and Section 7.5.3)
- Performance status (Section 7.4.2.6)
- Patient-reported QoL outcomes (Section 7.3.4.1 and Section 7.4.2.7)
- PROs (Section 7.4.2.7 and Section 7.6.3)
- Healthcare resource utilization within 6 months prior to enrolment (Section 7.7.3.4)
- Specific AE as per Section 7.4.2.4
- Pregnancies and pregnancy outcomes (Section 7.4.2.5)
- SAEs (see Section 9.1.1) and AEs (Section 7.4.2.4) leading to discontinuation or dose modification of an anti-cancer therapy (Section 9.1)

After the study completion/early termination visit, ongoing SAEs and ongoing treatment-related AEs should be followed as outlined in Section 9.1.4.1

7.4.2.1 Patient Medical History

Medical history will be collected as per routine clinical practice and, if available, recorded in the eCRF pages. The below is a non-exhaustive list of what could be captured:

- Past medical history includes surgeries, cardiovascular risk factors, comorbid medical conditions and their treatments, and other relevant medical history
- Past breast cancer history
 - At initial diagnosis: stage of disease; histology; hormone (oestrogen and progesterone) receptor status; metastatic sites (if stage IV at diagnosis); staging diagnostic work-up; and HER2 diagnostic method (in situ hybridization or immunohistochemistry) with results
 - Prior to diagnosis of unresectable LA/mBC: anti-cancer treatments in the early breast cancer setting (including radiotherapy; surgical treatments;

hormonal treatments; chemotherapies; and/or other pharmacological anti-cancer therapies, such as targeted therapies), reasons that led to treatment discontinuation or modification, and other clinically relevant information

- Breast cancer history after diagnosis of unresectable LA/mBC:
 - Sites of metastases
 - Disease status as assessed by the Investigator
 - Patient status, including left ventricular ejection fraction (LVEF), safety laboratory results, etc.
 - Anti-cancer treatment history for unresectable LA/mBC including:
 - Radiation treatment (including date, body site, dose and type of radiation)
 - Chemotherapy (including names, dates, doses, number of cycles per regimen and reasons [if any] for discontinuation)
 - Hormonal treatment (including agent name, administration route, date, dose and reasons [if any] for discontinuation)
 - Immunotherapy (including agent name, administration route, date, dose, number of cycles per regimen and reasons [if any] for discontinuation)
 - Other anti-cancer treatments including targeted therapies (including agent name, administration route, date, dose, number of cycles per regimen and reasons [if any] for discontinuation)
 - Surgery (including date, body site and type of procedure)

7.4.2.2 Demographics

Demographic data will be collected as per routine clinical practice and will include for example date of birth, sex, and self-reported ethnicity.

In addition, the following parameters will be recorded: employment status, premature retirement or employment resignation/termination due to the disease, occupation, educational status and place of residence, family income, insurance status and insurance type.

7.4.2.3 Anti-Cancer and Concomitant Medications

Data on all anti-cancer and concomitant medications will be collected and recorded in the CRF. This will include:

- All anti-cancer treatments received by the patient for breast cancer including during the period prior to enrolment
- Patients enrolled in an interventional clinical trial will have their study treatment(s) recorded, if open label and known, otherwise they will be recorded as “investigational treatment”
- All other medications (e.g. prescription drugs, over-the-counter drugs, herbal/homeopathic remedies, nutritional supplements) used by the patient within 14 days prior to enrolment and during the observation period

7.4.2.4 Collection of Safety Information

All routine clinical data, such as LVEF assessments, tumor assessments, routine blood work, etc. will be transcribed from patient charts, clinical notes, and diagnostic and laboratory test results and transcribed into the CRF (see Section 7.1 and Appendix 2)

The following specific AEs, serious and non-serious, will be recorded in the CRF during the observation period, with physician’s assessment of severity (mild, moderate, severe or in oncology studies using the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]) and relationship to therapy (i.e., related or unrelated) (See Appendix 4) .

All serious adverse events (SAE)

All AEs that leads to either discontinuation or dose modification of any anti-cancer treatment must be reported on the appropriate page of the CRF. Dose modification refers to any change in the prescribed quantity of drug and/or the dosing interval, including the withholding or delaying of doses.

Specific AEs only when observed concomitantly to the use of Roche products or their combination partner:

- Cases of potential medicine-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s law (see Section 9.1).
- Suspected transmission of an infectious agent by the study medicine, as defined below:
 - Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection in a patient exposed to a medicinal product. This

term only applies when a contamination of the study medicine is suspected and DOES NOT apply to infections supported by the mode of action, e.g. immunosuppression.

- Cardiac dysfunction, including one or more of the following:
 - Any fall in LVEF equal to or below 50% and/or clinically significant in the opinion of the treating physician and/or where a change in LVEF requires specific cardiovascular treatment and/or leads to discontinuation or delay of an anti-cancer treatment.
 - Congestive heart failure
 - Cardiac arrest
 - Cardiac ischemia/infarction
- Serious and non-serious pneumonitis

For the reporting of adverse events please refer to section 9.1.3.

7.4.2.5 Pregnancy Status and Pregnancy Outcomes

For this study, the pregnancy status of female patients and the outcome of any pregnancy will be collected at screening and during the observation period. Local laboratory pregnancy testing data (e.g. human β -chorionic gonadotropin) will be collected if available and may be used to determine pregnancy status.

For the reporting of pregnancy please refer to section 9.1.3.

7.4.2.6 Performance Status

Routine clinical assessments of patient performance status (e.g. Eastern Cooperative Oncology Group [ECOG] performance status) will be collected.

7.4.2.7 Quality of Life and Patient-Reported Outcomes

PROs will be collected at study enrolment and periodically throughout study participation, including at the clinic visit at approximately at 3-month intervals throughout the study period and during clinic visits that are determined by the treating physician (no specific visits will be mandated for collecting these data). The following QoL PROs will be used in this study:

- Work Productivity and Activity Impairment (WPAI) questionnaire: for patients who are working (Reilly Associates 2002)

7.4.2.8 Health Economic Outcome Measurements

Health economic outcome measurements (see Section 7.3.4.2 for details) will be collected at study entry for the 6-month period prior to enrolment and prospectively during the observation period.

This will include:

- Number (n) of hospitalisations
 - *Primary cause of hospitalisation*
 - *Hospitalisation length of stay*
 - *Level of care per hospitalisation*
 - ✓ *Length of stay in intensive care unit (ICU)*
 - ✓ *Length of stay in intermediate care unit (IMCU)*
 - ✓ *Length of stay in general ward*
 - ✓ *Length of stay in other unit*
 - *Procedures/interventions*
 - *Investigations*
 - *Medical treatment*
- Number of emergency room attendances not resulting to hospitalisation
 - *Primary cause of attendance*
 - *Procedures/interventions*
 - *Investigations*
 - *Medical treatment*
- Number of admissions to regular outpatient facilities
 - *Primary cause of visit*
 - *Procedures/interventions*
 - *Investigations*
 - *Medical treatment*
- Number of visits at office-based physicians
 - *Primary cause of visit*
 - *Procedures/interventions*
 - *Investigations*
 - *Medical treatment.*

Primary cause of hospitalisations, emergency room attendances and outpatient or private practice visits will be captured as disease-related, treatment-related (including AE/toxicity and pre-planned visits for treatment administration), comorbidity-related, and other.

Healthcare consumption due to treatment-related AEs/toxicities will furthermore include the following:

- Use of prophylactic or rescue supportive medications
- Use of red blood cell, platelet and plasma transfusions
- Medical procedures, laboratory tests, imaging or other diagnostic procedures
- Number of treatment days.

In addition, the out-of-pocket disease-related expenditures will be estimated, including:

- Private expenditures for pharmaceuticals, primary care, secondary care, examinations, formal paid nursing home care, and transportation to health care facilities.

Furthermore, the following additional information will be collected:

- Proportion of patients with premature retirement or termination of employment due to their condition
- Requirement for informal home care by family members or other informal non-family caregivers; employment status/profession of the family member/informal caregiver and number of working time missed for disease-related caregiving
- Proportion of patients requiring any type of formal or informal home care for their condition
- Any monetary social benefits that the patients receive due to her condition.

7.4.3 Data Collected at Study Completion

For subjects who complete the observation period, the study completion visit should be documented and the study completion page should be completed in the CRF.

7.5 PATIENT, STUDY, AND SITE DISCONTINUATION

7.5.1 Study Discontinuation

Patients have the right at any time and for any reason to withdraw their consent that their data are collected and used for the study.

When a patient faces end of life and decides to enter the hospice for end of life cares, the patient shouldn't be considered as discontinued from the study, although the patient does not receive any anti-cancer treatment anymore. Instead data from patient's charts and note will continue to be transferred into the CRF until study discontinuation.

The date of study discontinuation and final status (i.e. withdrawal of consent, physician's decision, loss to follow up or death) for a patient who discontinues from the study should be recorded in the eCRF.

7.5.2 Study and Site Discontinuation

The study initiator has the right to terminate this study at any time

7.5.3 Discontinuation from Anti-Cancer Treatment

Discontinuation of anti-cancer treatment will not be considered to be a reason for study discontinuation and patients will continue to be followed through the different lines of anti-cancer treatment and until study discontinuation. The treating physician is encouraged to follow the patient for as long as possible, until patient death or through to study end.

The decision for discontinuation from treatment lies with the treating physician in agreement with the patient's decision and is not regulated by this protocol.

7.6 DATA MANAGEMENT

7.6.1 Data Quality Assurance

This study will collect data from patients enrolled at each site. Patient medical records and patient-reported questionnaires will be used as data sources in this study. Local site staff will also provide appropriate patient information.

These data will be anonymized and entered into the CRF via a secure web-based EDC system.

The study initiator or designated contract research organization (CRO), as appropriate, will be responsible for data management of this study, including quality checking. Data entered manually will be captured via EDC using CRFs. Sites will be responsible for data entry into the EDC system. PROs will be collected on paper Case Report Forms, or captured electronically (PRO-CTCAE), and will be entered at a central facility, as determined by the Study Sponsor.

In the event of discrepant data, the study initiator or a designated CRO will request data clarification from the sites, which the sites will resolve electronically within the EDC system. CRFs and correction documentation will be maintained in the EDC system audit trail. System backups for data stored by the study initiator and records retention for the study data will be consistent with the study initiator's standard procedures.

The EDC system should meet approved established standards for the security of health information and be validated. The system should also meet the ICH guideline E6R1 regarding electronic study data handling and be available for audit upon request. Patient confidentiality will be strictly maintained.

Paper PRO questionnaires will be faxed or sent by courier from the site to a data-entry center.

The study initiator maintains high data quality standards and utilizes processes and procedures to repeatedly ensure that the data are as clean and as accurate as possible when presented for analysis. Data quality is enhanced through a series of programmed data quality checks that automatically detect and prevent the entry of out of range or

anomalous data. A remote data quality audit will be performed on collected data at various times throughout the study.

7.6.2 Electronic Case Report Forms

CRFs are to be completed using a study initiator's designated electronic data capture (EDC) system. Sites will receive training and have access to a manual for appropriate CRF completion. CRFs will be submitted electronically to the study initiator and should be handled in accordance with instructions from the study initiator. All CRFs should be completed by designated trained site staff. CRFs should be reviewed and electronically signed and dated by the physician or a designee.

At the end of the study, the physician will receive the data related to subjects from his or her site in an electronically readable format (e.g., on a compact disc). Data must be kept with the study records. Acknowledgement of receipt of the data is required.

7.6.3 Patient-Reported Outcome Data

In this study, PRO data will be elicited from the patients to more fully characterize the clinical profile of anti-cancer treatments.

In particular, the Greek version of EQ-5D-5L, FACT-B and WPAI-GH instruments will be administered to the patients via a paper-and-pencil self-administered format.

When the respondent has completed the questionnaires, the study physician shall review them to ensure all questions have been answered. If there are any missing questions, he/she shall point them out to the respondent so they may be completed. However, respondents may omit any question they do not feel comfortable answering.

In order to protect subject confidentiality the name of the patient will not be mentioned on the questionnaires.

Data recorded in the paper PROs will be entered in the EDC system at the Investigator's site. The Investigator will be responsible for entering data into the EDC system and according to the Investigator Instructions Manual. The Investigator Instructions Manual will also provide the site with data entry instructions.

Once the study is complete, the PRO (paper or electronic) data, audit trail and local information and system documentation will be archived. The Study Sponsor will provide each site Investigator with patient data for their site in both human- and machine-readable formats on an archival-quality compact disc that must be kept with the study records as source data. Acknowledgement of receipt of the compact disc is required.

7.6.4 Source Data Documentation

Site Operations Representative will perform ongoing SDV as defined in the Trial Monitoring Plan to confirm that critical protocol data (i.e., source data) entered in the CRF by authorized site personnel are accurate, complete, and verifiable from source documents.

Source documents (paper or electronic) are those in which subject data are recorded and documented for the first time. Before study initiation, the types of source documents that contain study-relevant information will be clearly defined in the Trial Monitoring Plan. The Trial monitoring plan defines which kind of source data – if available from clinical routine - can be used for documentation into CRF. No additional source data creation beyond routine is allowed.

Screening lists of those who chose to participate and those who declined participation in the study will be kept at the study site.

Source documents that are required to verify the validity and completeness of data entered in the CRF must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.6.6.

To facilitate SDV, the physicians and institutions must provide the marketing authorization holder direct access to applicable source documents and reports for trial-related monitoring, marketing authorization holder audits, and IRB/EC review. The participating sites must also allow inspection by applicable health authorities.

7.6.5 Use of Computerized Systems

When clinical observations are entered directly into a participating site's computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system allows preservation of the original entry of data. If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name of the person making the change, and date of the change.

7.6.6 Retention of Records

Records and documents pertaining to the conduct of this study as Informed Consent Forms, must be retained by the physician for at least 15 years after completion or discontinuation of the study, or for the length of time required by relevant national or local health authorities, whichever is longer. After that period of time, the documents may be destroyed, subject to local regulations.

No records may be disposed of without the written approval of the study initiator. Written notification should be provided to the study initiator prior to transferring any records to another party or moving them to another location.

7.7 STATISTICAL CONSIDERATIONS

For this study, a detailed data analysis plan will be included in the Statistical Analysis Plan.

7.7.1 General Considerations

The emphasis of this study is to observe trends in treatment regimens and their sequencing throughout the disease course, clinical outcomes (PFS, OS), and safety outcomes (incidence of SAEs, AEs leading to discontinuation or dose modification of an anti-cancer therapy, specific AEs and pregnancies) in patients with HER2-positive unresectable LA/mBC. Where possible, and if allowed by the number of patients enrolled receiving various anti-cancer treatment regimens, a comparative analysis of these clinical and safety outcomes across various HER2-targeted treatment regimens will also be performed. Patient characteristics associated with particular anti-cancer treatment regimens as well as the number of treatment regimens received by patients will be collected and examined to control for potential confounding when comparing treatment regimens.

The primary effectiveness objective of the study is to observe treatment regimens and their sequencing and to describe clinical outcomes in individual treatment groups. The planned sample size is intended to provide a sufficient number of patients to assess overall trends according to subgroups of common treatment regimens.

7.7.2 Analysis Populations

Effectiveness analyses will be based on all enrolled patients. Safety analyses will be carried out for all patients independently of the anti-cancer therapies they received.

7.7.3 Analysis Methods

The following is an outline of the statistical methodology that will be used to report and analyze data from this study. A more detailed description will be provided in a separate Statistical Analysis Plan, which may include additional exploratory analyses not explicitly mentioned below.

All enrolled patients who received at least one dose of an anti-cancer medication for HER2-positive unresectable LA/mBC will be included in the full analysis set, which will be the primary analysis population for safety and effectiveness parameters. Other analysis populations may be defined based on more restrictive criteria.

The analysis of the present study will be exploratory and primarily make use of descriptive statistical methods. In addition, exploratory statistical testing and modelling will be used to highlight interesting aspects of the data. Any test performed will be two-sided and carried out with a 5% α error rate without correction for multiplicity.

A descriptive analysis of safety will be performed. The main safety parameter is the incidence of SAEs. The proportion of patients experiencing at least one event within

each line of treatment will be estimated with 95% Clopper–Pearson confidence intervals (Cis).

The analysis of PFS and OS is based on the survivor function, which is the probability of remaining event free beyond a certain point in time. The survival function will be estimated using Kaplan–Meier methodology and summarized using the range, the 25th and 75th percentiles, the median overall survival and a 95% CI for the median. The plot of Kaplan–Meier estimates for the single treatment group will be presented.

7.7.3.1 Primary Effectiveness Analysis

The primary effectiveness objective for this study is to observe treatment regimens and their sequencing, and to describe treatment outcomes in patients with HER2-positive unresectable LA/mBC in the setting of normal clinical practice.

The numbers and proportions of patients receiving each unique treatment regimen overall and as first-line versus subsequent-line therapy will be summarized. First-line treatment regimens will be defined as therapies received after initial diagnosis of HER2 positive unresectable LA/mBC and before a patient experiences their first disease progression event.

For patients who receive more than one treatment regimen while on study, the proportion of patients receiving each unique treatment regimen sequence will also be summarized. Temporal changes in treatment patterns will be summarized across 6-month intervals.

7.7.3.2 Secondary Effectiveness Analysis

Where available, the following effectiveness parameters will be documented:

- Patient characteristics associated with receipt of particular anti-cancer treatment regimens
- OS for the overall population
- ORR for each treatment regimen: defined as the proportion of patients with either complete response (CR) or partial response (PR), based on their overall response. Response will be evaluated by the Investigator according to site-/country-specific medical practice.
- DoR for each anti-cancer treatment regimen: defined as the time from date of first response (CR or PR) to the date of disease progression, as per Investigator assessment.
- The number of treatment regimens received by patients

7.7.3.3 Safety Analysis

Where available, the following safety parameters will be documented:

- Comparative safety of various HER2-targeted treatment regimens and their combinations. This will be measured by comparing SAEs

- Incidence of treatment discontinuations due to SAEs or AEs
- Incidence of pregnancies during the observation period, as well as the incidence of abortions and pregnancy outcomes
- Safety profile based on AEs related to Roche oncology products in a real-world setting.
- Incidence of cardiac dysfunctions per line of treatment and type of anti-cancer therapy.

AEs will be coded and categorized, using the latest edition of Medical Dictionary for Regulatory Activities (MedDRA), by system organ class (SOC). Coded AEs will be tabulated by treatment group, SOC and preferred term for individual events within each body system. AEs will also be tabulated by severity and relationship to medication. AEs will be summarized separately. AEs associated with laboratory abnormalities will be listed.

7.7.3.4 Other Analyses

Quality of Life Outcome Analysis

Describe QoL PROs for each of the sequential treatment regimens using the following questionnaires: EQ-5D and FACT-B (see Section 7.3.4.1 and Section 7.4.2.7).

EQ-5D-5L

The distribution of patients by level ('no problems', 'slight problems', 'moderate problems', 'severe problems' and 'extreme problems') for each dimension (mobility, self-care, usual activities, pain/discomfort, anxiety / depression) of the EQ-5D questionnaire will be presented in frequency tables (N, %) for each study time point as well as per each anti-cancer treatment pattern.

The five levels of the EQ-5D-5L will be also dichotomized into 'no problems' (level 1 for all five dimensions) and 'problems' and the respective frequencies and percentages will be presented. Differences in the proportion of patients with 'no problems' vs. 'problems' among the various anti-cancer treatment regimens will be assessed using the chi-square test, if applicable.

Descriptive statistical measures (i.e., number, mean, median, SD and range) will be applied for the EQ-VAS score at time-points of interest as well as per treatment regimen and sequence. Mean changes of the EQ-VAS scores from study enrolment to the subsequent visits will be calculated. The Wilcoxon signed-rank test (or the paired t-test) will be used to assess potential differences in mean changes providing that the number of participants in each of the study time-points is sufficient to allow for meaningful inferences. No imputation methods will be performed in cases of missing values, while ambiguous answers (e.g. two boxes are ticked for a single dimension) will be treated as missing.

Differences in the EQ-VAS score between more than two treatment regimens at specific study time-points if considered of interest, may be examined using one-way ANOVA (or the non-parametric analogue). If the latter demonstrates statistically significant differences, further pairwise comparisons will be performed with the Tukey or Nemenyi post-hoc tests.

Finally, if applicable, Generalised Linear Models (GLM) will be used to assess the impact of the different anti-cancer treatment patterns on the EQ-VAS score.

FACT-B Questionnaire

Descriptive statistical measures (i.e., number, mean, median, SD and range) will be applied for all study visits and separately for each treatment regimen for the two assessment outcomes, FACT-B total score and TOI, which will be calculated as follows:

FACT-B Total Score = PWB score + SWB score +EWB score +FWB score +BCS score

FACT-B TOI= PWB score + FWB score + BCS score.

Negatively stated items are reversed by subtracting the response from “4”. After reversing proper items, all subscale items are summed to a total, which is the subscale score. A higher score in any FACT-B assessment indicates a better HRQoL.

It is noted that, the FACT scale is considered an acceptable indicator of patient QoL as long as the overall item response rate in the FACT-G (i.e. the PWB, SWB, EWB and FWB subscales) is greater than 80% (i.e. 22 of 27 items have been completed) and greater than 50% in the BCS subscale (i.e. 6 of 10 must have been completed).

If there are missing items, subscale scores can be prorated as long as more than 50% of the items of the specific subscale were answered. This scoring is performed by using the formula below:

$$\text{Prorated subscale score} = \frac{\text{Sum of item scores} \times \text{N of items in subscale}}{\text{Number of items answered}}$$

Mean changes in the FACT-B Total Score and the FACT-B TOI from study enrolment to the subsequent visits will be calculated providing the number of participants with available data in each of the study time-points is sufficient to allow for meaningful inferences. Differences between the mean changes will be assessed using the Wilcoxon signed-rank test (or the paired t-test).

Moreover, potential differences between the different treatment regimens pertaining to the FACT-B Total Score and FACT-B TOI score will be examined, if applicable. GLM may be applied in order to assess the impact of the different anti-cancer treatment patterns on the aforementioned scores.

Patient-Reported Outcomes Analysis

- Describe symptom burden, ability to perform activities of daily living and work productivity for each of the sequential treatment regimens using PROs: Work Productivity and Activity Impairment (WPAI) questionnaire: for patients who are working (Reilly Associates 2002)

Summary statistics (i.e. number, mean, median, SD and range) for WPAI-GH domain scores at study enrolment and at subsequent visits will be presented.

Similarly, descriptive statistics of the domain scores referring to the percentage of work time missed due to health (absenteeism); the percentage of impairment at work due to health (presenteeism), the percentage of overall work productivity loss due to health (absenteeism and presenteeism) and the percentage of daily activity impairment outside of work due to health, will be presented in tables for the different treatment regimens.

It is noted that while absenteeism and presenteeism are applicable only for patients who are employed, activity impairment due to health (item Q6 of the questionnaire) will be calculated for all respondents. For those who missed work and did not actually work in the past seven days, the percent overall work impairment due to health will be equal to the percent work time missed due to health.

If applicable, GLM will be applied in order to assess the effect of the different anti-cancer treatment regimens received by the patients during the study on the symptom burden, ability to perform activities of daily living and work productivity.

Healthcare Utilization and Cost Analysis

Healthcare resource utilization prior to unresectable LA/mBC diagnosis and sequencing of anti-cancer treatment regimens will be described:

- Utilization or adherence to predefined clinical guidelines regarding treatment regimen decisions
- Healthcare resource utilization and direct medical costs associated with the treatment of AEs, including associated procedures, hospitalizations, emergency room attendances and outpatient visits
-

All quantitative and qualitative outcome measurements described in Section 7.4.2.8, will be analyzed in descriptive manner for the subgroups of patients receiving the different anti-cancer treatment regimens and their sequences.

- With regard to hospitalisations, the hospitalisation rate in person-time will be estimated for each anti-cancer treatment regimen, overall and per primary cause of hospitalisation, along with the mean number of days that the patient was hospitalized. Likewise the respective rates of emergency room attendances, outpatient facility visits and office-based visits in person-time will be also calculated

7.7.4 Interim Analyses

For this study, there will be annual interim analyses for: safety reporting and presentation of safety results; presentation of the different treatment regimens and their sequencing. These annual reporting events will start 1 year after first patient first visit and will continue annually until study end. Effectiveness analyses may be performed provided that the number of enrolled patient allows such analysis. Data from other disease registries may be pooled to support the effectiveness and safety analyses.

7.7.5 Determination of Sample Size

This study will enrol a minimum of 300 patients over a 3-year period. Enrolled patients will receive various anti-cancer treatment regimens as determined by their treating physicians and according to the standard of care and/or clinical practice at each study site.

The primary effectiveness objective of the study is to observe treatment regimens and their sequencing and to describe treatment outcomes (PFS) in individual treatment groups. The planned sample size is intended to provide a sufficient number of patients to allow the assessment of overall trends by subgroups of common anti-cancer treatment regimens.

In order to assess the adequacy of the sample size for the precision of median PFS time – the primary measure of effectiveness – simulated exponential survival times were generated and evaluated 1000 times for sample sizes ranging from 100 to 1000 (with a 3-year enrolment period and 5-year follow-up period from the last patient enrolled).

The median PFS time used in the simulations was approximately 10 months. The results show that with 600 patients the expected 95% confidence interval (CI) for the median will extend from 8.85 to 11.16 months (a width of 2.32 months). The precision of this estimate is deemed sufficient to draw valid conclusions around this measure of effectiveness. Table 1 and Figure 1. show the expected estimates of the 95% CIs for the median PFS using different sample sizes.


In regards to the sample size of 300 patients planned to be enrolled in Greece, with an approximate median PFS time of 10 months, the expected 95% CI will range from 8.41 to 11.66 months (i.e., a width of 3.25 months) as indicated in bold in Table 1.

Table 1. Estimated 95% CIs for a Median Progression-free Survival of 10 Months

No. of patients	Lower 95% CI (months)	Upper 95% CI (months)	Width of CI (months)
100	7.23	13.04	6.01
200	8.02	12.04	4.02
300	8.41	11.66	3.25
400	8.59	11.52	2.93
500	8.80	11.33	2.53
600	8.85	11.16	2.31
700	8.93	11.07	2.14
800	9.02	11.04	2.02
900	9.09	10.94	1.85
1000	9.11	10.87	1.76

Abbreviation: CI = confidence interval.

Figure 1. Estimated Median PFS Times and Their 95% CIs as a Function of Sample Sizes



Abbreviations: CI = confidence interval; PFS = progression-free survival.

Figure 1 suggests that an increase in sample size up to 300 patients results in noticeably increased precision (tighter 95% CI) of measuring PFS of up to 10 months when a study sizes of 100 to 1000 were examined. Increasing the sample size beyond 300 does not yield a substantial increase in precision. For instance, in measuring a median PFS time of 10 months, the width of the estimated 95% CI is 4.02 months for a sample size of 200 versus 2.02 months for a sample size of 800.


An additional simulation study was performed to evaluate the precision of median OS time for sample sizes from 100 to 1000. The median OS time used in this simulation was 24 months. With 600 patients, the expected CI for median OS will extend from 21.3 to 26.9 months (a width of 5.6 months). Table 2 and Figure 2 show the expected estimates of the 95% CIs for the median OS using different sample sizes.

Table 2. Estimated 95% Confidence Intervals for a Median Overall Survival of 24 Months

No. of patients	Lower 95% CI (months)	Upper 95% CI (months)	Width of CI (months)
100	17.48	31.31	13.83
200	19.32	28.93	9.61
300	20.24	28.07	7.83
400	20.70	27.56	6.86
500	21.08	27.19	6.11
600	21.29	26.86	5.57
700	21.49	26.58	5.09
800	21.55	26.40	4.85
900	21.75	26.27	4.52
1000	21.87	26.16	4.29

CI = confidence interval.
CI = confidence interval.

Figure 2. Estimated Median OS Times and Their 95% Confidence Intervals as a Function of Sample Sizes



Abbreviations: CI = confidence interval; OS = overall survival.

In relation to the measures of safety, assuming that a specific event occurs in 1% of patients in the study (e.g. a specific SAE), with 600 patients the 95% Clopper–Pearson CI around that incidence will extend from 0.37% to 2.2%. For events occurring in 10% of patients, the CI will extend from 7.7% to 12.7%. The precision of these CIs and the probability to detect rare events is deemed sufficient to draw valid conclusions concerning the events of interest.

Table 3 shows the estimated 95% CIs for different event rates.

Table 3. Estimated 95% Confidence Intervals for Different Event Rates

No. of Patients		Event rate				
		0.1% (1/1000)	1% (1/100)	2% (2/100)	5% (5/100)	10% (1/10)
200	95% CI, %	0.0–2.0	0.12–3.6	0.05–5.0	2.4–9.0	6.2–15.0
400	95% CI, %	0.0–1.1	0.2–2.5	0.87–3.9	3.1–7.6	7.2–13.4
600	95% CI, %	0.0–0.8	0.37–2.2	1.0–3.5	3.4–7.1	7.7–12.7
800	95% CI, %	0.0–0.65	0.4–2.0	1.1–3.2	3.6–6.7	8.0–12.3
1000	95% CI, %	0.0–0.5	0.48–1.8	1.2–3.1	3.7–6.5	8.2–12.0

Table 4 shows the probability of detecting occurrences for different event rates with different sample sizes.

Table 4. Probability of Detecting Occurrences for Different Event Rates

No. of patients		Event rate				
		0.1% (1/1000)	1% (1/100)	2% (2/100)	5% (5/100)	10% (1/10)
200	Probability of detecting at least one event	0.18	0.87	0.98	1.0	1.0
400	Probability of detecting at least one event	0.33	0.98	1.0	1.0	1.0
600	Probability of detecting at least one event	0.45	1.0	1.0	1.0	1.0
800	Probability of detecting at least one event	0.55	1.0	1.0	1.0	1.0
1000	Probability of detecting at least one event	0.63	1.0	1.0	1.0	1.0

A Statistical Analysis Plan will be developed to provide further detail on statistical analyses and a schedule for interim analyses.

7.8 STUDY DOCUMENTATION AND MONITORING

7.8.1 Study Documentation

The physician must maintain adequate and accurate records to enable the conduct of the study to be fully documented, including but not limited to the protocol, protocol amendments, Informed Consent Forms, and documentation of IRB/EC.. In addition, at the end of the study, the physician will receive the patient data, which include an audit trail containing a complete record of all changes to data.

Before study initiation, the types of source documents that are to be generated will be clearly defined in the Study Monitoring Plan. This includes any protocol data to be entered directly into the CRFs (i.e. no prior written or electronic record of the data) and considered source data.

Source documents that are required to verify the validity and completeness of data entered into the CRFs must not be obliterated or destroyed and must be retained as detailed in the policy for retention of records (see Section 7.6.6).

7.8.2 Site Audits and Inspections

Site visits will be conducted by the study initiator or an authorized representative for audit of study data, subjects' medical records, and CRFs.

The physician will also permit national and local health authorities to inspect facilities and records relevant to this study.

7.8.3 Administrative Structure

The trials will be sponsored and managed by Roche Hellas S.A.. Approximately 10 sites will participate in the study and approximately 300 patients will be enrolled. Enrollment will be performed through a manual management system.

All laboratory tests will be performed by the Investigator according to clinical judgement and routine clinical practice.

7.9 LIMITATIONS OF THE RESEARCH METHOD

As any other disease registry, patient selection bias may be an issue. To minimize patient selection bias, the Investigator (or sub-Investigator) should invite all eligible consecutive patients.

7.10 OTHER ASPECTS

Not applicable

8. PROTECTION OF HUMAN SUBJECTS

8.1 COMPLIANCE WITH LAWS AND REGULATIONS

This study will be conducted in full conformance with the Guidelines for GPP published by the International Society of Pharmacoepidemiology (ISPE) and the laws and regulations of the country in which the research is conducted.

The procedures set out in this study protocol are designed to ensure that the Sponsor and Investigator abide by the applicable local and regional laws and regulations.

This study will also comply with the definition of the non-interventional (observational) study provided in Article 2(c) of Directive 2001/20/EC (available at <http://eur-lex.europa.eu>) and its refinement provided in Chapter 1.7 Section 1 of Volume 9A of the Rules Governing Medicinal Products in the European Union (available at http://ec.europa.eu/health/documents/eudralex/vol-9/index_en.htm), the amended definition for Post-Authorisation Safety Studies to Directive 2001/83/EC in Article 1(c) of Directive 2001/83/EU (available at http://ec.europa.eu/health/documents/eudralex/vol-9/index_en.htm), and its refinement provided in Guideline of Good Pharmacovigilance Practices (GVP) Module VIII – Post-Authorisation Safety Studies (available at

http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129137.pdf).

This study will be conducted in compliance with this protocol and in accordance with the ethical principles that have their origin in the Declaration of Helsinki (available at <http://www.wma.net/en/30publications/10policies/b3/>) and will be consistent with the Council for International Organizations of Medical Sciences International Ethical Guidelines for Biomedical Research Involving Human Subjects (available at http://www.cioms.ch/publications/layout_guide2002.pdf) and the GCP guidelines (available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf). The study will also follow the International Society of Pharmacoepidemiology Guidelines on GPP (available at http://www.pharmacoepi.org/resources/guidelines_08027.cfm), the International Ethical Guidelines for Epidemiological Studies (available at <http://www.ufrgs.br/bioetica/cioms2008.pdf>), as well as all other applicable regulatory requirements. The study will also abide by the European Federation of Pharmaceutical Industries and Associations Code on the Promotion of Prescription-only Medicines to and Interactions With, Healthcare Professionals (available at: <http://transparency.efpia.eu/uploads/Modules/Documents/efpia-hcp-code---2013-consolidated-final-2.pdf>).

Study personnel involved in conducting this trial will be qualified by education, training and experience to perform their respective task(s).

8.2 INFORMED CONSENT

The study initiator's sample Informed Consent Form (and ancillary sample Informed Consent Forms such as a Child's Assent or Caregiver's Informed Consent Form, if applicable) will be provided to each site.

The Consent Forms must be signed and dated by the subject or the subject's legally authorized representative before start of documentation of his or her data in the CRF. The case history or clinical records for each subject shall document the informed consent process and that written informed consent was obtained prior to first documentation of this subject's data in the CRF.

By signing the form, the subject confirms that he/she has been informed about the study and agrees to pseudonymous data collection, pooling of data with similar scientific data (if applicable), and the possibility of monitoring activities. It is the responsibility of the physician to obtain written informed consent from each subject participating in the study, after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study. The physician must also explain that the subject is completely free to refuse to enter the study or to withdraw from it at any time, for any reason and without

losing the benefit of any medical care to which the subject is entitled or is presently receiving.

A copy of each signed Consent Form must be provided to the subject or the subject's legally authorized representative. All signed and dated Consent Forms must remain in each subject's study file or in the site file and must be available for verification by study monitors at any time.

8.3 INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE

This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Site Operations Representative in consultation with the Scientific Responsible and reviewed and approved by the IRB/EC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/EC.

8.4 CONFIDENTIALITY

The study initiator maintains confidentiality standards by coding each subject enrolled in the study through assignment of a unique subject identification number. This means that subject names are not included in datasets that are transmitted to any study initiator's location. Access to the EDC system will be controlled via hierarchical username and password control.

Patient medical information obtained by this study is confidential and may be disclosed to third parties only as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

The anonymized data, as entered into the EDC system, will be visible to the CRO and the Study Initiator, but only center staff will be able to trace a case identification number back to a patient's true identity, a necessary measure to allow centre staff to respond to data queries raised by the CRO later. Detailed explanation of data protection and patient confidentiality measures will be included in each application for local ethics approval.

Medical information may be given to a patient's personal physician or other appropriate medical personnel responsible for the patient's welfare, for treatment purposes.

Data generated by this study must be available for inspection upon request by representatives of national and local health authorities, marketing authorization holder monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate.

9. MANAGEMENT OF ADVERSE EVENTS

Disease registries are recognized as a source of adverse event reporting, and while it is not a requirement to collect all AEs as part of a disease registry, any AEs which are collected in the course of the registry should be forwarded to the **Marketing Authorization Holder as solicited reports.**

In addition, the following should also be reported if occurring during exposure to a marketed medicinal product:

- pregnancy
- abnormal laboratory findings with or without associated AEs (see Section 9.1)
- overdose, abuse, misuse, medication error, occupational exposure with or without associated AEs
- reports of lack of efficacy
- drug interactions

Certain types of events require immediate reporting to the Sponsor, as outlined in Section 9.1.1.

9.1 ADVERSE EVENTS

According to the International Conference of Harmonisation (ICH), an AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following:

- Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
- Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition)
- Recurrence of an intermittent medical condition (e.g., headache) not present at baseline
- Any deterioration in a laboratory value or other clinical test (e.g., electrocardiogram [ECG], X-ray) that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study medicine.

Any AE that leads to either discontinuation or dose modification of an anti-cancer treatment must be reported on the appropriate page of the CRF. Dose modification refers to any change in the prescribed quantity of drug and/or the dosing interval, including the withholding or delaying of doses.

9.1.1 Assessment of Serious Adverse Events (Immediately Reportable to the Marketing Authorization Holder) and Other Non-Serious Adverse Events

Serious Adverse Events

An SAE is any AE that meets any of the following criteria:

- Is fatal (i.e., the AE actually causes or leads to death)
- Is life-threatening (NOTE: The term “life-threatening” refers to an event in which the patient was at immediate risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.)
- Requires or prolongs inpatient hospitalization (see Appendix 4)
- Results in persistent or significant disability/incapacity (i.e., the AE results in substantial disruption of the patient’s ability to conduct normal life functions)
- Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study medicine
- Is a significant medical event in the physician’s judgment (e.g., may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above)

The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to NCI CTCAE criteria; see Appendix 4); the event itself may be of relatively minor medical significance (such as severe headache without any further findings).

Severity and seriousness need to be independently assessed for each AE recorded on the CRF.

SAEs related to Roche products are required to be immediately reported by the physician to the Sponsor (i.e., no more than 24 hours after learning of the event; see Section 9.1.3).

Non-Serious Adverse Events

For this disease registry, all non-serious AEs must be collected as per protocol section 7.4.2.4.

9.1.2 Methods and Timing for Capturing and Assessing Safety Parameters

The physician is responsible for ensuring that all AEs collected as per protocol (see Section 9.1 for definition) are recorded in the AE section of the CRF and reported to the marketing authorization holder in accordance with instructions provided in this section and in Appendix 4.

For each AE recorded in the AE section of the CRF, the physician will make an assessment of seriousness, severity, and causality (see Appendix 4).

9.1.2.1 Adverse Event Reporting Period

All AEs collected in this registry are subject to the collecting and reporting requirements outlined in this protocol. Whether reported by the patient or noted by the site's personnel, AEs should be recorded in the patient's medical record and transcribed to the AE section of the CRF. Particular attention should be given to AEs described in section 7.4.2.4, which **must be collected** for the registry to meet its objectives.

Once the patient is enrolled in the study, AEs will be collected until the end of the observation period. After this period, the physician is not required to actively monitor patients for AEs but if the treating physician becomes aware of any related AEs to any Roche medicinal product they should be notified to the competent authority in the Member State where the reactions occurred or to the marketing authorization holder of the suspected medicinal product, but not to both (to avoid duplicate reporting).

9.1.2.2 Procedures for Recording Adverse Events

It is recommended that physicians use correct medical terminology/concepts when recording AEs in the patients' record and in the AE section of the CRF. Colloquialisms and abbreviations should be avoided.

Only one AE term should be recorded in the event field of the CRF.

See Appendix 4 for further specific instruction regarding:

- Infusion-Related or Injection Reactions
- Diagnosis versus signs and symptoms
- Adverse Events occurring secondary to other Adverse Events
- Persistent or recurrent Adverse Events
- Abnormal Laboratory Values
- Abnormal Vital Sign Values
- Abnormal Liver Function Tests
- Deaths
 - All events with an outcome or consequence of death should be classified as serious adverse events (SAEs) and reported to the marketing authorization holder immediately. In certain circumstances, however, suspected adverse reactions with fatal outcome may not be subject to expedited reporting (see Section 7.6). All deaths that occur during the protocol-specified AE reporting period, regardless of relationship to study medicine, must be recorded in the AE section of the CRF and immediately reported to the marketing authorization holder
- Pre-existing Medical Conditions
- Hospitalization or Prolonged Hospitalization

- Overdoses, Misuses, Abuses, Off-Label Use, Occupational Exposure, or Medication Error (including potentially exposed in case of medication error or intercepted medication error) or Quality Defects
- Quality Defects and Falsified Medicinal Products

9.1.3 Reporting Requirements from Physician to Marketing Authorisation Holder

9.1.3.1 Immediate Reporting Requirements from Physician to Marketing Authorization Holder

Certain events require immediate reporting to allow the Marketing Authorization Holder and the regulatory authorities to take appropriate measures to address potential new risks associated with the use of the medicine. The physician must report such events to the marketing authorization holder immediately; under no circumstances should reporting take place more than 24 hours after the physician learns of the event. The following is a list of events that the physician must report to the marketing authorization holder within 24 hours after learning of the event, regardless of relationship to study medicine:

- SAEs

The physician must report new significant follow-up information for these events to the marketing authorization holder immediately (i.e., no more than 24 hours after becoming aware of the information). New significant information includes the following:

- New signs or symptoms or a change in the diagnosis
- Significant new diagnostic test results
- Change in causality based on new information
- Change in the event's outcome, including recovery
- Additional narrative information on the clinical course of the event

For reports of SAEs, including follow-up, physicians should record all case details that can be gathered immediately (i.e., within 24 hours) in the AE page of the CRF and submit the report via the EDC system. A report will be generated and sent to Roche Drug Safety by the EDC system.

In the event that the EDC system is temporarily unavailable, please refer to Section 9.1.3.3. Pregnancy should not be recorded on the Adverse Event eCRF but by submitting a paper Pregnancy Reporting Form (see section 9.1.3.4).

Physicians must also comply with local requirements for reporting SAEs to the local health authority and IRB/EC.

9.1.3.2 Reporting Requirements for Non-Serious Adverse Events

For all non-serious AEs, including follow-up reports, physicians must record all case details that can be gathered within 30 calendar days of learning of the event on the AE section of the CRF and submit the report via the EDC system. A report will be

generated and sent to Roche Drug to allow appropriate reporting to relevant competent authorities.

In the event that the EDC system is temporarily unavailable, please refer to Section 9.1.3.3.

9.1.3.3 If EDC System is Temporarily Unavailable or not Used

In the event that the EDC system is temporarily, a completed paper reporting form and fax coversheet should be faxed/scanned to Roche Drug Safety or its designee immediately (i.e., no more than 24 hours after learning of the event) or within 30 days for non-serious AEs, using the fax number or email address provided to physicians.

Once the system is available again, all information should additionally be entered and submitted via the EDC system.

9.1.3.4 Reporting Requirements for Pregnancies

Female patients of childbearing potential will be instructed to immediately inform the physician if they become pregnant during the observation period. A Pregnancy Report should be completed by the physician immediately (i.e., no more than 24 hours after learning of the pregnancy and sent to Roche Drug Safety). Pregnancy should not be recorded on the AE CRF. Monitoring of the patient should continue until conclusion of the pregnancy. Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the AE section of the CRF.

Suspected adverse reactions that occur in infants following exposure to a medicinal product from breast milk should also be reported to Roche Drug Safety.

9.1.4 Follow-Up of Patients after Adverse Events

9.1.4.1 Physician Follow-Up

The physician should follow each AE until the event has resolved to baseline grade or better, the event is assessed as stable by the physician, the patient is lost to follow-up, or the patient withdraws consent. Every effort should be made to follow all SAEs considered to be related to studied medicinal product until a final outcome can be reported.

During the study period, resolution of AEs (with dates) should be documented in the AE section of the CRF and in the patient's medical record to facilitate SDV.

All pregnancies reported during the study should be followed until pregnancy outcome.

9.1.4.2 Marketing Authorization Holder Follow-Up

For all AEs, the Marketing Authorization Holder or a designee may follow up by telephone, fax and/or electronic mail, to obtain additional case details and outcome

information from the disease registry in order to perform an independent medical assessment of the reported case.

9.2 SAFETY REPORTING REQUIREMENTS FOR NON-STUDIED MEDICINAL PRODUCTS

In the context of this disease registry, all medicinal products used to treat the disease are considered studied products. Any other products should be considered as non-studied products.

Although adverse event information is not being actively solicited for non-studied medicinal products, the physician/consumers are reminded to report any adverse reactions (for which they suspect a causal role of a medicinal product) that come to their attention to the marketing authorization holder of the suspected medicinal product, or to the concerned competent authorities via the national spontaneous reporting system.

10. PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS

Regardless of the outcome of a study, the study initiator is dedicated to openly providing information on the trial to healthcare professionals and to the public, both at scientific congresses and in peer-reviewed journals. The study initiator will comply with all requirements for publication of study results.

The results of this study may be published or presented at scientific meetings. If this is foreseen, the physician must agree to submit all manuscripts or abstracts to the study initiator prior to submission for publication or presentation. This allows the study initiator to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the physician.

In accordance with standard editorial and ethical practice, study initiator will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating physician will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors' authorship requirements. Any formal publication of the study in which contribution of the study initiator personnel exceeded that of conventional monitoring will be considered as a joint publication by the physician and the appropriate study initiator's personnel.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of data from this study will become and remain the exclusive and unburdened property of the study initiator, except where agreed otherwise.

Safety results will be published or presented at scientific meetings locally. Effectiveness, Health economic and other measures may be published provided that the number of patients enrolled is sufficient.

11. **SAFETY RESULTS WILL BE BE PUBLISHED OR PRESENTED AT SCIENTIFIC MEETINGS. EFFECTIVENESS RESULTS MAY BE PUBLISHED PROVIDED THAT THE NUMBER OF PATIENTS ENROLLED IS SUFFICIENT. REFERENCES**

Aaronson NK, Ahmedzai S, Bergman B, et al. for the European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. *J Natl Cancer Inst* 1993;85:365–376.

Austin CD, De Mazière AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. *Mol Biol Cell* 2004;15:5268–5282.

Baselga J, Cameron D, Miles D, et al. Objective response rate in a Phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. *J Clin Oncol (Meeting Abstracts)* June 2007 vol. 25 no. 18_suppl 1004

Brady MJ, Cella DF, Mo F, et al. Reliability and Validity of the Functional Assessment of Cancer Therapy-Breast Quality-of-Life Instrument. *J Clin Oncol* 1997; 15: 974-986

Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. *J Clin Oncol* 2011;29:398-405.

Centers for Disease Control (CDC) and Prevention. Measuring Healthy Days. Atlanta, Georgia: CDC, November 2000. See http://www.cdc.gov/hrqol/hrqol14_measure.htm

de Haes JCJM, Olschewski M, Fayers P, et al. The Rotterdam Symptom Checklist (RSCL): A manual. Northern Centre for Healthcare Research, 1996.

Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. *Cancer Res* 2006;66:4426–4433

Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med* 2006;355:2733–2743.

Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. *Semin Oncol* 2006;33:15–49.

Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. *CA Cancer J Clin* 2011;61:69–90.

Jeyakumar A, Younis T. Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations. *Clinical Medicine Insights. Oncology* 2012;6:179–187.

Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. *J Clin Oncol* 2005; 23:4265–4274.

National Cancer Institute Cancer Therapy Evaluation Program. 2013. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

National Cancer Institute. Patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 2012. Available at: <http://outcomes.cancer.gov/tools/pro-ctcae>

Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines—Part II. *J Am Acad Dermatol* 2004;51:440–447.

Owens MA, Horten BC, Da Silva MM HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. *SOClin Breast Cancer*. 2004;5(1):63.

Portera CC, Walshe JM, Denduluri N, et al. A report of cardiac events in a Phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer. *J Clin Oncol* 2007;25(18S):1028. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. *Ann Med* 2001;33:337–343.

Reilly Associates. Work Productivity and Activity Impairment Questionnaire (WPAI). 2002. Available at: <http://www.reillyassociates.net/Index.html>.

Rugo HS, Kaufman PA, Yood MU, et al. registHER: an observational cohort study of survival of patients with HER2-positive metastatic breast cancer and use of trastuzumab following progression. Poster presentation at the San Antonio Breast Cancer Symposium; San Antonio, TX, USA; 10–14 December 2008.

Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer; correlation of relapse and survival with amplification of the HER2/neo oncogene. *Science* 1987;235:177–182.

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344:783–792.

Spector NL, Xia W, Burris H 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. *J Clin Oncol* 2005;23:2502–2512.

Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. *J Clin Oncol* 1996;14:2756–2768

Sundaresan S, Penuel E, Sliwkowski MX. The biology of human epidermal growth factor receptor 2. *Curr Oncol Rep* 1999;1:16–22.

Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 2013;14:461–471.

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012;367:1783–1791.

Welslau M, Diéras V, Sohn J-H, et al. Patient-reported outcomes from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer. *Cancer*. 2014 Mar 1;120(5):642-51

Wildiers H, Kim S B, Gonzalez Martin A, et al. T-DM1 for HER2-positive MBC: primary results from TH3RESA, a phase 3 study of T-DM1 versus treatment of physician choice. Presented at: European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract LBA15.

World Health Organization. World Health Statistics; 2011.
http://www.who.int/whosis/whostat/EN_WHS2011_Full.pdf

Appendix 1 Data Collection Overview

Table 7. Summary of Data Collected During the Observation Study

Prior to the start of study-related data collection	At enrolment	Periodic data collection at approximately 3 months, at death, or study discontinuation
<p>Informed consent (Section 8.2)</p>	<p>Demographic data (Section 7.4.2.2)</p> <p>Patient past medical history, including surgeries, cardiovascular risk factors, comorbid medical conditions and their treatments, and other relevant medical history (7.4.2.1)</p> <p>Breast cancer specific history (from initial diagnosis) including details regarding early breast cancer (Section 7.4.2.1)</p> <p>Anti-Cancer treatments (radiation, chemotherapy, hormonal, and/or other anti-cancer therapy such as targeted therapy) for unresectable LA/mBC along with reasons for changes (Section 7.3.1.1 and Section 7.4.2.3)</p> <p>Characteristics of the investigational site, e.g. type of healthcare provider, type and size of hospital (Section 7.1.4)</p> <p>Concomitant medications (Section 7.4.2.3)</p> <p>Disease and performance status (Section 7.4.2.6)</p>	<p>Changes in medical history (Section 7.4.2.1)</p> <p>Changes in breast cancer history (e.g. interval surgeries, site of metastases, disease status; Section 7.4.2.1)</p> <p>Anti-Cancer treatments (radiation, chemotherapy, hormonal, and/or other anti-cancer therapy such as targeted therapy) along with reasons for changes (Section 7.3.1.1 and Section 7.4.2.3)</p> <p>Concomitant medications (Section 7.4.2.3)</p> <p>Disease and performance status (Section 7.4.2.6)</p>
	<p>Patient-reported QoL (Section 7.4.2.7)</p>	<p>Patient-reported QoL (Section 7.4.2.7)</p>
	<p>PROs (Section 7.6.3)</p> <p>Healthcare resource utilization (Section 7.7.3.4)</p> <p>Pregnancy status (Section 7.4.2.5)</p>	<p>PROs</p> <p>Healthcare resource utilization (Section 7.7.3.4)</p> <p>Pregnancy status and pregnancy outcome</p> <p>SAEs (Section 9.1.1), AEs leading to discontinuation or modification of an anti-cancer therapy, specific AEs (section 7.4.2.4)</p>
<p>Abbreviations: AE = adverse event; BC = breast cancer; PRO = patient-reported outcome; SAE = serious adverse event; ADR = adverse drug reaction.</p>		

Appendix 2 Data Collected During the Observational Study

Assessment	Timepoint		
	Prior to start of study-related data collection	Enrolment	Approximately every 3 months, at death, or discontinuation ^a
Informed consent	X		
Demographic data		X	
Healthcare provider type	X		
Medical history			
Cardiovascular risk factors		X	
Other relevant medical history		X	X ^b
Selected laboratory tests		X	X ^b
LVEF value		X	X ^b
BC-specific cancer history ^c		X	X ^b
BC treatments ^{b,c,d}		X	X ^{b,d}
Interval surgical and radiotherapy administration			X ^{b,d}
Interval anti-cancer therapy administration			X ^b
Disease status		X	X
Selected concomitant medications		X	X ^{b,d}
ECOG performance status		X	X
Quality of life assessments ^e		X	X
Work productivity/activity impairment ^f		X	X
Healthcare resource utilisation and out-of-pocket expenses ^g		X	X
Safety events ^h			Continuous
Pregnancy and pregnancy outcome		X	X

Assessment	Timepoint		
	Prior to start of study-related data collection	Enrolment	Approximately every 3 months, at death, or discontinuation ^a
<p>Abbreviations: AE = adverse event; BC = breast cancer; ECOG = Eastern Cooperative Oncology Group; EQ-5D = EuroQol 5-Dimensions questionnaire; HER2 = human epidermal growth factor receptor 2; LVEF = left ventricular ejection fraction; SAE = serious adverse event.</p> <p>a Data will be collected at approximately 3-month intervals throughout the study period during clinic visits that are determined by the treating physician (no specific visit will be mandated for collecting these data).</p> <p>b Reporting of changes in patient history, BC-specific history, selected tests, LVEF values, BC treatments and concomitant medications during the course of this observational study.</p> <p>c To include stage (at time of initial diagnosis and enrolment), histology, oestrogen receptor/progesterone receptor status, HER2 status (fluorescence <i>in situ</i> hybridization/immunohistochemistry) and BC archival HER2 status including any HER2 retesting performed during to enrolment and throughout the observation period, staging diagnostic work-up, metastatic sites, and presence or absence of central nervous system metastases. HER2 status repeated during later lines of treatment should also be captured in the CRF.</p> <p>d All cancer treatments, including any changes to them, as well as treatments for any AEs</p> <p>e The following quality of life assessments will be collected on-site: EQ-5D and FACT-B</p> <p>f The WPAI:GH questionnaire will be used to assess the health-related work productivity loss and activity impairment.</p> <p>g Healthcare resource utilisation and out-of-pocket expenses will be collected from the time of unresectable LA/mBC diagnosis until study observation period completion (where it is routine clinical practice).</p> <p>h Including all SAEs, AEs leading to treatment discontinuation or modification, and specific AEs. SAEs must be reported to Sponsor within 24 hours of learning of the events.</p>			

Appendix 3 ENCePP Checklist for Study Protocols (Revision 2)

Adopted by the ENCePP Steering Group on 14/01/2013

The [European Network of Centres for Pharmacoepidemiology and Pharmacovigilance \(ENCePP\)](#) welcomes innovative designs and new methods of research. This Checklist has been developed by ENCePP to stimulate consideration of important principles when designing and writing a pharmacoepidemiological or pharmacovigilance study protocol. The Checklist is intended to promote the quality of such studies, not their uniformity. The user is also referred to the [ENCePP Guide on Methodological Standards in Pharmacoepidemiology](#) which reviews and gives direct electronic access to guidance for research in pharmacoepidemiology and pharmacovigilance.

For each question of the Checklist, the Investigator should indicate whether or not it has been addressed in the study protocol. If the answer is “Yes”, the page number(s) of the protocol where this issue has been discussed should be specified. It is possible that some questions do not apply to a particular study (for example in the case of an innovative study design). In this case, the answer ‘N/A’ (Not Applicable) can be checked and the “Comments” field included for each section should be used to explain why. The “Comments” field can also be used to elaborate on a “No” answer.

This Checklist should be included as an Annex by marketing authorization holders when submitting the protocol of a non-interventional post-authorization safety study (PASS) to a regulatory authority (see the [Guidance on the format and content of the protocol of non-interventional post-authorization safety studies](#)). Note, the Checklist is a supporting document and does not replace the format of the protocol for PASS as recommended in the Guidance and Module VIII of the Good Pharmacovigilance Practices (GVP).

Section 1: Milestones	Yes	No	N/A	Page Number(s)
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection ¹	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
1.1.2 End of data collection ¹	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
1.1.3 Study progress report(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
1.1.4 Interim progress report(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

¹ Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.

¹ Date from which the analytical dataset is completely available.

Appendix 3

Schedule of Pharmacodynamic and Pharmacokinetic Assessments (cont.)

Section 1: Milestones	Yes	No	N/A	Page Number(s)
1.1.5 Registration in the EU PAS register	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
1.1.6 Final report of study results.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

Section 2: Research question	Yes	No	N/A	Page Number(s)
2.1 Does the formulation of the research question and objectives clearly explain:				
2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
2.1.2 The objective(s) of the study?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
2.1.3 The target population? (i.e. population or subgroup to whom the study results are intended to be generalized)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
2.1.4 Which formal hypothesis(-es) is (are) to be tested?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
2.1.5 If applicable, that there is no <i>a priori</i> hypothesis?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

Section 3: Study design	Yes	No	N/A	Page Number(s)
3.1 Is the study design described? (e.g. cohort, case-control, randomized controlled trial, new or alternative design)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
3.2 Does the protocol specify the primary and secondary (if applicable) endpoint(s) to be investigated?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
3.3 Does the protocol describe the measure(s) of effect? (e.g. relative risk, odds ratio, deaths per 1000 person-years, absolute risk, excess risk, incidence rate ratio, hazard ratio, number needed to harm (NNH) per year)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

Section 4: Source and study populations	Yes	No	N/A	Page Number(s)
4.1 Is the source population described?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
4.2 Is the planned study population defined in terms of:				
4.2.1 Study time period?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
4.2.2 Age and sex?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
4.2.3 Country of origin?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
4.2.4 Disease/indication?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
4.2.5 Comorbidity?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Appendix 3

Schedule of Pharmacodynamic and Pharmacokinetic Assessments (cont.)

<u>Section 4: Source and study populations</u>	Yes	No	N/A	Page Number(s)
4.2.6 Seasonality?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
4.3 Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 5: Exposure definition and measurement</u>	Yes	No	N/A	Page Number(s)
5.1 Does the protocol describe how exposure is defined and measured? (e.g. operational details for defining and categorising exposure)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
5.2 Does the protocol discuss the validity of exposure measurement? (e.g. precision, accuracy, prospective ascertainment, exposure information recorded before the outcome occurred, use of validation sub-study)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
5.3 Is exposure classified according to time windows? (e.g. current user, former user, non-use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
5.4 Is exposure classified based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
5.5 Does the protocol specify whether a dose-dependent or duration-dependent response is measured?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 6: Endpoint definition and measurement</u>	Yes	No	N/A	Page Number(s)
6.1 Does the protocol describe how the endpoints are defined and measured?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
6.2 Does the protocol discuss the validity of endpoint measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, prospective or retrospective ascertainment, use of validation sub-study)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 7: Confounders and effect modifiers</u>	Yes	No	N/A	Page Number(s)
7.1 Does the protocol address known confounders? (e.g. collection of data on known confounders, methods of controlling for known confounders)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
7.2 Does the protocol address known effect modifiers? (e.g. collection of data on known effect modifiers, anticipated direction of effect)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Appendix 3

Schedule of Pharmacodynamic and Pharmacokinetic Assessments (cont.)

Comments:

--

Section 8: Data sources	Yes	No	N/A	Page Number(s)
8.1 Does the protocol describe the data source(s) used in the study for the ascertainment of: 8.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview, etc.) 8.1.2 Endpoints? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics, etc.) 8.1.3 Covariates?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
8.2 Does the protocol describe the information available from the data source(s) on: 8.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber) 8.2.2 Endpoints? (e.g. date of occurrence, multiple event, severity measures related to event) 8.2.3 Covariates? (e.g. age, sex, clinical and drug use history, comorbidity, co-medications, life style, etc.)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
8.3 Is a coding system described for: 8.3.1 Diseases? (e.g. International Classification of Diseases (ICD)-10) 8.3.2 Endpoints? (e.g. Medical Dictionary for Regulatory Activities (MedDRA) for adverse events) 8.3.3 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC) Classification System)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
8.4 Is the linkage method between data sources described? (e.g. based on a unique identifier or other)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

Section 9: Study size and power	Yes	No	N/A	Page Number(s)
9.1 Is sample size and/or statistical power calculated?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

Section 10: Analysis plan	Yes	No	N/A	Page Number(s)
10.1 Does the plan include measurement of excess risks?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
10.2 Is the choice of statistical techniques described?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
10.3 Are descriptive analyses included?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
10.4 Are stratified analyses included?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Appendix 3

Schedule of Pharmacodynamic and Pharmacokinetic Assessments (cont.)

<u>Section 10: Analysis plan</u>	Yes	No	N/A	Page Number(s)
10.5 Does the plan describe methods for adjusting for confounding?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
10.6 Does the plan describe methods addressing effect modification?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 11: Data management and quality control</u>	Yes	No	N/A	Page Number(s)
11.1 Is information provided on the management of missing data?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
11.2 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
11.3 Are methods of quality assurance described?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
11.4 Does the protocol describe possible quality issues related to the data source(s)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
11.5 Is there a system in place for independent review of study results?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 12: Limitations</u>	Yes	No	N/A	Page Number(s)
12.1 Does the protocol discuss: 12.1.1 Selection biases? 12.1.2 Information biases? (e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods)	<input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>	
12.2 Does the protocol discuss study feasibility? (e.g. sample size, anticipated exposure, duration of follow-up in a cohort study, patient recruitment)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
12.3 Does the protocol address other limitations?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 13: Ethical issues</u>	Yes	No	N/A	Page Number(s)
13.1 Have requirements of Ethics Committee/Institutional Review Board approval been described?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
13.2 Has any outcome of an ethical review procedure been addressed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Appendix 3

Schedule of Pharmacodynamic and Pharmacokinetic Assessments (cont.)

<u>Section 13: Ethical issues</u>	Yes	No	N/A	Page Number(s)
13.3 Have data protection requirements been described?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 14: Amendments and deviations</u>	Yes	No	N/A	Page Number(s)
14.1 Does the protocol include a section to document future amendments and deviations?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 15: Plans for communication of study results</u>	Yes	No	N/A	Page Number(s)
15.1 Are plans described for communicating study results (e.g. to regulatory authorities)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
15.2 Are plans described for disseminating study results externally, including publication?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

Name of the main author of the protocol: _____

Date: / /

Signature: _____

Appendix 4 Adverse Events

Appendix 4.1	Assessment of Severity of Adverse Events
Appendix 4.2	Assessment of Causality of Adverse Events
Appendix 4.3	Procedures for Recording Adverse Events

Appendix 4.1 Assessment of Severity of Adverse Events

The AE severity grading scale for the NCI CTCAE (v 4.0) will be used for assessing AE severity. The table below will be used for assessing severity for AEs that are not specifically listed in the NCI CTCAE.

Adverse Event Severity Grading Scale

Grade	Severity
1	Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated
2	Moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living ^a
3	Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living ^{b, c}
4	Life-threatening consequences or urgent intervention indicated ^d
5	Death related to AE ^d

Note: Based on the NCI CTCAE (v 4.0), which can be found at:

http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

^a Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

^b Examples of self-care activities of daily living include bathing, dressing and undressing, feeding oneself, using the toilet, and taking medications, as performed by patients who are not bedridden.

^c If an event is assessed as a “significant medical event,” it must be reported as an SAE (see Section 9.1.3.1 for reporting instructions), per the definition of SAE in Section 9.1.1.

^d Grade 4 and 5 events must be reported as SAEs (see Section 9.1.3.1 for reporting instructions), per the definition of SAE in Section 9.1.1.

Appendix 4.2 Assessment of Causality of Adverse Events

Physicians should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether or not an AE is considered to be related to the study medicine, indicating “yes” or “no” accordingly. The following guidance should be taken into consideration:

- Temporal relationship of event onset to the initiation of study medicine

- Course of the event, considering especially the effects of dose reduction, discontinuation of study medicine, or reintroduction of study medicine (when applicable)
- Known association of the event with the study medicine or with similar treatments
- Known association of the event with the disease under study
- Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event
- Presence of non-treatment-related factors that are known to be associated with the occurrence of the event

For patients receiving combination therapy, causality will be assessed individually for each of the medicinal product.

Appendix 4.3 Procedures for recording Adverse Events

Appendix 4.3.1 Infusion-Related or Injection Reactions AEs that occur during or within 24 hours after studied medicinal product administration should be captured as individual signs and symptoms in the AE section of the CRF rather than an overall diagnosis (e.g., record dyspnea and hypotension as separate events rather than a diagnosis of infusion-related reaction or anaphylactic reaction).

Appendix 4.3.2 Diagnosis versus Signs and Symptoms

For AEs, other than infusion-related or injection reactions (see Appendix 5.3.1) a diagnosis (if known) should be recorded in the AE section of the CRF rather than individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded in the AE section of the CRF. If a diagnosis is subsequently established, all previously reported AEs based on signs and symptoms should be nullified and replaced by one AE report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis.

Appendix 4.3.3 Adverse Events Occurring Secondary to Other Events

In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be identified by their primary cause, with the exception of severe or serious secondary events. A medically significant secondary AE that is separated in time from the initiating event should be recorded as an independent event in the AE section of the CRF. For example:

- If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting should be reported on the CRF.
- If vomiting results in severe dehydration, both events should be reported separately on the CRF.
- If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported separately on the CRF.
- If dizziness leads to a fall and subsequent fracture, all three events should be reported separately on the CRF.
- If neutropenia is accompanied by an infection, both events should be reported separately on the CRF.

All AEs should be recorded separately in the AE section of the CRF if it is unclear as to whether the events are associated.

Appendix 4.3.4 Persistent or Recurrent Adverse Events

A persistent AE is one that extends continuously, without resolution, between patient evaluation timepoints. Such events should only be recorded once in the AE section of the CRF. The initial severity (intensity or grade) of the event will be recorded at the time the event is first reported. If a persistent AE becomes more severe, the most extreme severity should also be recorded in the AE section of the CRF. If the event becomes serious, it should be reported to the marketing authorization holder immediately (i.e., no more than 24 hours after learning that the event became serious; see Section 9.1.3.1 for reporting instructions). The AE section of the CRF should be updated by changing the event from "non-serious" to "serious," providing the date that the event became serious, and completing all data fields related to SAEs.

A recurrent AE is one that resolves between patient's evaluation timepoints and subsequently recurs. Each recurrence of an AE should be recorded separately in the AE section of the CRF.

Appendix 4.3.5 Abnormal Laboratory Values

Not every laboratory abnormality qualifies as an AE. A laboratory test result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy
- Is clinically significant in the physician's judgment

It is the physician's responsibility to review all laboratory findings. Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.

If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline phosphatase and bilirubin $5 \times$ the upper limit of normal [ULN] associated with cholestasis), only the diagnosis (i.e., cholestasis) should be recorded in the AE section of the eCRF.

If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded in the AE section of the CRF, along with a descriptor indicating if the test result is above or below the normal range (e.g., "elevated potassium," as opposed to "abnormal potassium"). If the laboratory abnormality can be characterized by a precise clinical term per standard definitions, the clinical term should be recorded as the AE. For example, an elevated serum potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."

Observations of the same clinically significant laboratory abnormality from visit to visit should only be recorded once in the AE section of the eCRF (see Appendix 5.3.4 for details on recording persistent AEs).

Appendix 4.3.6 Abnormal Vital Sign Values

Not every vital sign abnormality qualifies as an AE. A vital sign result must be reported as an AE if it meets any of the following criteria:

- Is accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention or a change in concomitant therapy
- Is clinically significant in the physician's judgment

It is the physician's responsibility to review all vital sign findings. Medical and scientific judgment should be exercised in deciding whether an isolated vital sign abnormality should be classified as an AE.

If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded in the AE section of the CRF.

Observations of the same clinically significant vital sign abnormality from visit to visit should only be recorded once in the AE section of the CRF (see Appendix 5.3.4 for details on recording persistent AEs).

Appendix 4.3.7 Abnormal Liver Function Tests

The finding of an elevated ALT or AST ($> 3 \times$ the baseline value) in combination with either an elevated total bilirubin ($> 2 \times$ the ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury. Therefore, physicians must report as an AE the occurrence of either of the following:

- Treatment-emergent ALT or AST $> 3 \times$ the baseline value in combination with total bilirubin $> 2 \times$ the ULN (of which $\geq 35\%$ is direct bilirubin), except in patients with documented Gilbert's syndrome. For patients with Gilbert's syndrome, elevation of direct bilirubin $> 2 \times$ ULN should be used instead.
- Treatment-emergent ALT or AST $> 3 \times$ the baseline value in combination with clinical jaundice

The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded in the AE section of the CRF (see Appendix 5.3.5) and reported to the marketing authorization holder immediately (i.e., no more than 24 hours after learning of the event).

Appendix 4.3.8 Deaths

For this protocol, mortality is a secondary effectiveness objective (Section 6.2).

- Deaths that are attributed by the physician solely to progression of breast cancer should be recorded only on the Study Completion/Early Discontinuation CRF. They will not be considered an SAE for the purposes of this study and are thus exempt from expedited reporting.
- All other deaths that occur during the observational period, regardless of relationship to therapy, must be recorded on the AE CRF and immediately reported to the marketing authorization holder as a SAE (see Section 9.1.1).

Death should be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the AE section of the CRF. Generally, only one such event should be reported. The term “**sudden death**” should only be used for the occurrence of an abrupt and unexpected death due to presumed cardiac causes in a patient with or without preexisting heart disease, within 1 hour after the onset of acute symptoms or, in the case of an unwitnessed death, within 24 hours after the patient was last seen alive and stable. If the cause of death is unknown and cannot be ascertained at the time of reporting, “**unexplained death**” should be recorded on the AE section of the CRF. If the cause of death later becomes available (e.g., after autopsy), “unexplained death” should be replaced by the established cause of death.

Appendix 4.3.9 Preexisting Medical Conditions

A preexisting medical condition is one that is present at the screening visit for this study. Such conditions should be recorded on the General Medical History and Baseline Conditions in the CRF.

A preexisting medical condition should be recorded as an AE only if the frequency, severity, or character of the condition worsens during the study. When recording such events in the AE section of the CRF, it is important to convey the concept that the preexisting condition has changed by including applicable descriptors (e.g., “more frequent headaches”).

Appendix 4.3.10 Hospitalization or Prolonged Hospitalization

Any AE that results in hospitalization or prolonged hospitalization should be documented and reported as an SAE (per the definition of SAE in Section 9.1.1), except as outlined below.

The following hospitalization scenarios are not considered to be SAEs:

- Hospitalization for respite care
- Hospitalization for a preexisting condition, provided that all of the following criteria are met:

- The hospitalization was planned prior to the study or was scheduled during the study when elective surgery became necessary because of the expected normal progression of the disease.
 - The patient has not suffered an AE.
- Hospitalization was solely related to progression of the underlying breast cancer

Appendix 4.3.11 Overdoses, Misuses, Abuses, Off-Label Use, Occupational Exposure, or Medication Error or Quality Defects

Any overdose, misuse, abuse, off-label use, occupational exposure, medication error, or any other incorrect administration of medicine under observation should be noted in the Drug Administration section of the CRF. Any overdose, abuse, misuse, inadvertent/erroneous administration, medication error, or occupational exposure reports must be forwarded to the marketing authorization holder with or without an AE.

Reports with or without an AE should be forwarded to the marketing authorization holder as per non-serious timelines. If the associated AE fulfills the seriousness criteria, the event should be reported to the marketing authorization holder immediately (i.e., no more than 24 hours after learning of the event, see Section 9.1.3.1).

For the purpose of reporting cases of suspected adverse reactions, an occupational exposure to a medicine means an exposure to a medicine as a result of one's professional or non-professional occupation.

Appendix 4.3.12 Quality Defects and Falsified Medicinal Products

Reports of suspected or confirmed falsified medicinal product or quality defect of a medicinal product, with or without an associated AE, should be forwarded to the marketing authorization holder as per non-serious timelines. If the associated AE fulfills the seriousness criteria, the event should be reported to the marketing authorization holder immediately (i.e., no more than 24 hours after learning of the event, see Section 9.1.3.1).